本文へ移動

病院

文字サイズ

  • 小
  • 中
  • 大

 

外来診療・時間外診療・救急外来　電話：0562-46-2311

ホーム > 病院 > 病院について > 組織 > 代謝内科部

代謝内科部

対象疾患

高齢期の糖尿病・内分泌疾患および骨粗鬆症

最近の話題

これまでの在籍医師

  役職 在任期間
谷川隆久 内科医師 平成26年1月1日～令和2年3月31日
細井孝之 臨床研究推進部長 平成17年7月1日～平成25年7月31日
玉腰暁子 治験管理室長 平成18年1月1日～平成19年10月31日
吉山(中村)範美 内科医師 平成16年4月1日～平成19年8月31日
村本あき子 内科レジデント 平成16年3月1日～平成16年8月31日

代謝内科

2023年

欧文原著

  1. Ida H, Onuma T, Nakashima D, Mizutani D, Hori T, Ueda K, Hioki T, Kim W, Enomoto Y, Doi T, Matsushima-Nishiwaki R, Yamaguchi S, Tachi J, Tanabe K, Ogura S, Iwama T, Kozawa O, Tokuda H. Tramadol regulates the activation of human platelets via Rac but not Rho/Rho-kinase. PLoS One. 2023;18:e0279011.
  2. Sugimoto T, Tokuda H, Miura H, Kawashima S, Ando T, Kuroda Y, Matsumoto N, Fujita K, Uchida K, Kishino Y, Sakurai T. Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes. Diabetes Obes. Metab. 2023;25:222-228.
  3. Nishikimi A, Nakagawa T, Fujiwara M, Watanabe K, Watanabe A, Komatsu A, Yasuoka M, Watanabe R, Naya M, Oshima H, Kitagawa Y, Tokuda H, Kondo I, Niida S, Sakurai T, Kojima M, Arai H. Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan. J. Infect. 2023;86:e33-e35.
  4. Kuroyanagi G, Hioki T, Tachi J, Matsushima-Nishiwaki R, Iida H, Kozawa O, Tokuda H. Oncostatin M stimulates prostaglandin D2-induced osteoprotegerin and interleukin-6 synthesis in osteoblasts. Prostaglandins Leukot. Essent. Fatty Acids. 2023;192:102575.
  5. Hioki T, Kuroyanagi G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Oncostatin M attenuates tumor necrosis factor-alfa-induced synthesis of macrophage-colony stimulating factor via suppression of Akt in osteoblasts. Connect. Tissue Res. 2023;64:139-147.
  6. Li J, Nakagawa T, Kojima M, Nishikimi A, Tokuda H, Nishimura K, Umezawa J, Tanaka S, Inoue M, Ohmagari N, Yamaguchi K, Takeda K, Yamamoto S, Konishi M, Miyo K, Mizoue T. Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study. PLoS One. 2023;18:e0283658.
  7. Enomoto Y, Onuma T, Hori T, Tanabe K, Ueda K, Mizutani D, Doi T, Matsushima-Nishiwaki R, Ogura S, Iida H, Iwama T, Kozawa O, Tokuda H. Synergy by ristocetin and CXCL12 in human platelet activation: Divergent regulation by Rho/Rho kinase and Rac. Int. J. Mol. Sci. 2023;24:9716.
  8. Kuroyanagi G, Hioki T, Tachi J, Matsushima-Nishiwaki R, Iida H, Tokuda H, Kozawa O. Resveratrol inhibits basic fibroblast growth factor-induced macrophage colony-stimulating factor synthesis via the PI3-kinase/Akt pathway in osteoblasts. Biosci. Biotechnol. Biochem. 2023;87:1462-1469. 
  9. Sugimoto T, Tokuda H, Miura H, Kawashima S, Omura T, Ando T, Kuroda Y, Matsumoto N, Fujita K, Uchida K, Kishino Y, Sakurai T. Longitudinal association of continuous glucose monitoring-derived metrics with cognitive decline in older adults with type 2 diabetes: A 1-year prospective observational study. Diabetes Obes. Metab. 2023;25:3831-3836.
  10. Kuroyanagi G, Hioki T, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. HSP70 inhibitor amplifies the bFGF‑induced release of IL‑6 in osteoblasts. Mol. Med. Rep. 2023;28:230. 
  11. Hioki T, Tachi J, Ueda K, Matsushima-Nishiwaki R, Iida H, Kozawa O, Tokuda H. Oncostatin M enhances osteoprotegerin synthesis but reduces macrophage colony‑stimulating factor synthesis in bFGF‑stimulated osteoblast‑like cells. Exp. Ther. Med. 2023;27:34.
  12. Kawai Y, Watanabe Y, Omae Y, Miyahara R, Khor SS, Noiri E, Kitajima K, Shimanuki H, Gatanaga H, Hata K, Hattori K, Iida A, Ishibashi-Ueda H, Kaname T, Kanto T, Matsumura R, Miyo K, Noguchi M, Ozaki K, Sugiyama M, Takahashi A, Tokuda H, Tomita T, Umezawa A, Watanabe H, Yoshida S, Goto Y, Maruoka Y, Matsubara Y, Niida S, Mizokami M, Tokunaga K. Exploring the genetic diversity of the Japanese population: Insights from a large-scale whole genome sequencing analysis. PLoS Genet. 2023;19:e1010625.
  13. Omura T, Katsumi A, Kawashima S, Naya M, Tokuda H. Prolonged COVID-19 infection in a patient with complete remission from follicular lymphoma with hyperosmolar hyperglycemic syndrome. Geriatrics. 2023;8:110.

先頭へ戻る

2022年

欧文原著

  1. Hioki T, Kuroyanagi G, Fujita K, Sakai G, Kawabata T, Kim W, Tachi J, Matsushima-Nishiwaki R, Iida H, Kozawa O, Tokuda H. Incretins enhance PGF2alfa-induced synthesis of IL-6 and osteoprotegerin in osteoblasts. Horm. Metab. Res. 2022;54:42-49.
  2. Nishikimi A, Watanabe K, Watanabe A, Yasuoka M, Watanabe R, Oshima H, Kitagawa Y, Tokuda H, Niida S, Kojima M. Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan. J. Infect. 2022;84:e23-e25.
  3. Mizutani D, Tokuda H, Onuma T, Uematsu K, Nakashima D, Ueda K, Doi T, Enomoto Y, Matsushima-Nishiwaki R, Ogura S, Iida H, Kozawa O, Iwama T. Amyloid-beta protein negatively regulates human platelet activation induced by thrombin receptor-activating protein. Biosci. Biotechnol. Biochem. 2022;86:185-198.
  4. Doi T, Hioki T, Tachi J, Ueda K, Matsushima-Nishiwaki R, Iida H, Ogura S, Kozawa O, Tokuda H. Oncostatin M reduces the synthesis of macrophage-colony stimulating factor stimulated by TGF-beta via suppression of p44/p42 MAP kinase and JNK in osteoblasts. Biomed. Res. 2022;43:41-51. 
  5. Kuroyanagi G, Tokuda H, Fujita K, Kawabata T, Sakai G, Kim W, Hioki T, Tachi J, Matsushima-Nishiwaki R, Otsuka T, Iida H, Kozawa O. Upregulation of TGF-beta-induced HSP27 by HSP90 inhibitors in osteoblasts. BMC Musculoskelet Disord. 2022;23:495.
  6. Doi T, Hori T, Onuma T, Mizutani D, Ueda K, Enomoto Y, Matsushima-Nishiwaki R, Tanabe K, Hioki T, Tokuda H, Iwama T, Iida H, Kozawa O, Ogura S. Thrombopoietin and collagen in low doses cooperatively induce human platelet activation. Acute. Med. Surg. 2022;9:e769.
  7. Kuroyanagi G, Kawabata T, Tokuda H, Fujita K, Matsushima-Nishiwaki R,  Sakai G, Tachi J, Hioki T, Kim W, Iida H, Otsuka T, Kozawa O. Attenuation by HSP90 inhibitors of EGF-elicited migration of osteoblasts: Involvement of p44/p42 MAP kinase. Connect. Tissue Res. 2022;63:359-369.
  8. Nishikimi A, Watanabe K, Watanabe A, Yasuoka M, Watanabe R, Fujiwara M, Oshima H, Nakagawa T, Kitagawa Y, Tokuda H, Washimi Y, Niida S, Kojima M. Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey. J. Infect. 2022;85:174-211.
  9. Yamamoto S, Tanaka A, Ohmagari N, Yamaguchi K, Ishitsuka K, Morisaki N, Kojima M, Nishikimi A, Tokuda H, Inoue M, Tanaka S, Umezawa J, Okubo R, Nishimura K, Konishi M, Miyo K, Mizoue T. Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers. Prev. Med. 2022 ;161:107123.
  10. Nishikimi A, Nakagawa T, Fujiwara M, Watanabe K, Watanabe A, Komatsu A, Yasuoka M, Watanabe R, Naya M, Oshima H, Kitagawa Y, Tokuda H, Kondo I, Niida S, Sakurai T, Kojima M, Arai H. Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan. J. Infect. 2022;S0163-4453(22)00621-1.
  11. Hioki T, Matsushima-Nishiwaki R, Tokuda H, Kozawa O. Selective estrogen receptor modulators, acting as agonists of estrogen receptor α in osteoblasts, reduce the TGF-beta-induced synthesis of macrophage colony-stimulating factor via inhibition of JNK signaling pathway. Biomed. Res. 2022;43:211-221.
  12. Hori T, Mizutani D, Onuma T, Okada Y, Kojima K, Doi T, Enomoto Y, Iida H, Ogura S, Sakurai T, Iwama T, Kozawa O, Tokuda H. Relationship between the responsiveness of amyloid beta protein to platelet activation by TRAP stimulation and brain atrophy in patients with diabetes mellitus. Int. J. Mol. Sci. 2022;23:14100.
  13. Kuroyanagi G, Tachi J, Fujita K, Kawabata T, Sakai G, Nakashima D, Kim W, Tanabe K, Matsushima-Nishiwaki R, Otsuka T, Iida H, Kozawa O, Tokuda H. HSP70 inhibitors upregulate prostaglandin E1-induced synthesis of interleukin-6 in osteoblasts. PLoS One. 2022;17:e0279134.

先頭へ戻る

2021年

欧文原著

  1. Hioki T, Tokuda H, Nakashima D, Fujita K, Kawabata T, Sakai G, Kim W, Tachi J, Tanabe K, Matsushima-Nishiwaki R, Otsuka T, Iida H, Kozawa O. HSP90 inhibitors strengthen extracellular ATP-stimulated synthesis of interleukin-6 in osteoblasts: Amplification of p38 MAP kinase. Cell Biochem. Funct. 2021;39:88-97.
  2. Kuroyanagi G, Sakai G, Otsuka T, Yamamoto N, Fujita K, Kawabata T, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. HSP22 (HSPB8) positively regulates PGF2α-induced synthesis of interleukin-6 and vascular endothelial growth factor in osteoblasts. J. Orthop. Surg. Res. 2021;16:72.
  3. Kim W, Tokuda H, Tanabe K, Yamaguchi S, Hioki T, Tachi J,  Matsushima-Nishiwaki R, Kozawa O, Iida H. Acetaminophen reduces osteoprotegerin synthesis stimulated by PGE2 and PGF2α in osteoblasts: Attenuation of SAPK/JNK but not p38 MAPK or p44/p42 MAPK. Biomed. Res. 2021;42:77-84.
  4. Sable-Morita S, Tanikawa T, Satake S, Okura M, Tokuda H, Arai H.Microvascular complications and frailty can predict adverse outcomes in older patients with diabetes. Geriatr. Gerontol. Int. 2021;21:359-363.
  5. Tachi J, Onuma T, Yamaguchi S, Kim W, Hioki T, Matsushima-Nishiwaki R, Tanabe K, Tokuda H, Kozawa O, Iida H. Duloxetine suppresses BMP-4-induced release of osteoprotegerin via inhibition of the SMAD signaling pathway in osteoblasts. Biochem. Cell. Biol. 2021;99:578-586.
  6. Sable-Morita S, Okura M, Tanikawa T, Kawashima S, Tokuda H, Arai H.Associations between diabetes-related foot disease, diabetes, and age-related complications in older patients. Eur. Geriatr. Med. 2021;12:1003-1009.
  7. Sugimoto T, Arai A, Fujita H, Honda K, Inagaki N, Ishida T, Kato J, Kishi M, Kobayashi K, Kouyama K,　Noma H, Ohishi M, Satoh-Asahara N, Shimada H, Sugimoto K, Suzuki S, Takeya Y, Tamura Y, Tokuda H, Umegaki H, Watada H, Yamada Y, Sakurai T. The multi-domain intervention trial in older adults with diabetes mellitus for prevention of dementia in Japan: Study protocol for a multi-center, randomized, 18-month controlled rial. Front. Aging Neurosci. 2021;13:680341.
  8. Hioki T, Tokuda H, Kuroyanagi G, Kim W, Tachi J, Matsushima-Nishiwaki R,  Iida H, Kozawa O. Olive polyphenols attenuate TNF-α-stimulated M-CSF and IL-6 synthesis in osteoblasts: Suppression of Akt and p44/p42 MAP kinase signaling pathways. Biomed. Pharmacother. 2021;141:111816.
  9. Hioki T, Tokuda H, Tanabe K, Kim W, Tachi J, Yamaguchi S, Matsushima-Nishiwaki R, Kozawa O, Iida H. Amplification by tramadol of PGD2-induced osteoprotegerin synthesis in osteoblasts: Involvement of μ-opioid receptor and 5-HT transporter. Prostaglandins Leukot Essent. Fatty Acids. 2021;172:102323.
  10. Sable-Morita S, Arai Y, Takanashi S, Aimoto K, Okura M, Tanikawa ,T, Maeda K, Tokuda H, Arai H. Development and testing of the foot care scale for older Japanese diabetic patients. Int. J. Low. Extrem. Wounds. 2021;15347346211045033. Online ahead of print.
  11. Kaneda H, Ida Y, Kuwahara R, Sato I, Nakano T, Tokuda H, Sato T, Murakoshi T, Honke K, Kotani N. Proximity proteomics has potential for extracellular vesicle identification. J. Proteome. Res. 2021;20:3519-3531.
  12. Nishikimi A, Kojima M, Watanabe K, Watanabe A, Yasuoka M, Oshima H, T Okuda H, Niida S. Seroprevalence of antibodies against SARS-CoV-2 among workers in a national research institute and hospital in central Japan. GHM Open. 2021;1:40-42.

著書

  1. 川嶋修二, 谷川隆久, 徳田治彦：合併症への対応 b糖尿病とMCI, 鳥羽研二（監修）, 櫻井　孝, 服部英幸,         　武田章敬, 佐治直樹（編集）, “認知症サポート医・認知症初期集中支援チームのための認知症診療ハンドブック” ,  pp112-115, ㈱南江堂, 東京, 2021年4月15日発行．

先頭へ戻る

2020年

欧文原著

  1. Kawabata T, Tokuda H, Kuroyanagi G, Fujita K, Sakai G, Kim W, Matsushima-Nishiwaki R, Iida H, Yata K, Wang S, Mizoguchi A, Otsuka T,   Kozawa O. Incretin accelerates platelet-derived growth factor-BB-induced osteoblast migration via protein kinase A: The upregulation of p38 MAP kinase. Sci. Rep. 2020;10:2341.
  2. Tokuda H, Kusunose M, Senda K, Kojima K,Onuma T, Kojima A, Mizutani D, Enomoto Y, Iwama T, Iida H, Kozawa O. The release of phosphorylated-HSP27 from activated platelets of obstructive sleep apnea syndrome (OSAS) patients. Respir. Investig. 2020;58:117-127.
  3. Mizutani D, Onuma T, Tanabe K, Kojima A, Uematsu K, Nakashima D, Doi T, Enomoto Y, Matsushima-Nishiwaki R, Tokuda H, Ogura S, Iida H, Kozawa O, Iwama T. Olive polyphenol reduces the collagen-elicited release of phosphorylated HSP27 from human platelets. Biosci. Biotechnol. Biochem.    2020;84:536-543.
  4. Onuma T, Iida M, Kito Y, Tanabe K, Kojima A, Nagase K, Uematsu K, Enomoto Y, Doi T, Tokuda H, Ogura S, Iwama T, Kozawa O, Iida H. Cigarette smoking cessation temporarily enhances the release of phosphorylated-HSP27 from human platelets. Intern. Med. 2020;59:1841-1847.
  5. Hioki T, Kawabata T, Sakai G, Fujita K, Kuroyanagi G, Matsushima-Nishiwaki R, Kim W, Otsuka T, Iida H, Tokuda H, Kozawa O. Resveratrol suppresses insulin-like growth factor I-induced osteoblast migration: attenuation of the p44/p42 MAP kinase parhway. Biosci. Biotechnol. Biochem. 2020;84:2428-2439.
  6. Kim W, Tanabe K, Kuroyanagi G, Matsushima-Nishiwaki R, Fujita K, Kawabata T, Tachi J, Hioki T, Nakashima D, Yamaguchi S, Otsuka T, Tokuda H, Kozawa O,  Iida H. Tramadol enhances PGF2alfa-stimulated osteoprotegerin synthesis in osteoblast. Heliyon. 2020;6:e04779.
  7. Tachi J, Tokuda H, Omuma T, Yamaguchi S, Kim W, Hioki T, Matsushima-Nishiwaki R, Tanabe K, Kozawa O, Iida H. Duloxetine strengthens osteoblast activation by prostaglandin E1: Upregulation of p38 MAP kinase. Prostaglandins Other Lipid Mediat. 2020;151:106481. 
  8. Nakashima D, Onuma T, Tanabe K, Kito Y, Uematsu K, Mizutani D, Enomoto Y, Tsujimoto M, Doi T, Matsushima-Nishiwaki R, Tokuda H, Ogura S, Iwama T, Kozawa O, Iida H. Synergistic effect of collagen and CXCL12 in the low doses on human platelet activation. PLoS One. 2020;15:e0241139.

著書

  1. 徳田治彦 : 人間ドックの上手な利用法, 荒井秀典（編）, 40歳からの健康年表, 文春新書1260, 株式会社文藝春秋, 東京, 2020年4月20日, pp270-283.

学会発表等

  1. 徳田治彦, 川端哲, 新飯田俊平, 小澤修
    ストレス蛋白質（HSP)90は骨芽細胞において血小板由来増殖因子（PDGF-BB)により惹起される細胞遊走を促進的に制御する-p44/p42 mitogen-activated protein kinase(MAPK)経路の関与-
    第62回日本老年医学会学術集会, 2020年8月4-6日, 誌上発表.

                                                                                                                                 先頭へ戻る

2019年

欧文原著​

  1. Kim W, Tokuda H, Kawabata T, Fujita K, Sakai G, Nakashima D, Tachi J, Kuroyanagi G, Matsushima-Nishiwaki R, Tanabe K, Otsuka T, Iida H, Kozawa O. Enhancement by HSP90 inhibitor of PGD2-stimulated HSP27 induction in osteoblasts: suppression of SAPK/JNK and p38 MAP kinase. Prostaglandins Other Lipid Mediat. 2019:1;143:106327. doi: 10.1016/j.prostaglandins. 2019.03.002.
  2. Ogama N, Sakurai T, Kawashima S, Tanikawa T, Tokuda H, Satake S, Miura H, Shimizu A, Kokubo M, Niida S, Toba K, Umegaki H, Kuzuya M. Association of glucose fluctuations with sarcopenia in older adults with Type 2 diabetes mellitus. J. Clin. Med. 2019;8:pii: E319. doi: 10.3390/jcm8030319.
  3. Fujita K, Otsuka T, Kawabata T, Sakai G, Kim W, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Wnt3a downregulates thyroid hormone-induced osteocalcin expression in osteoblasts. Exp. Ther. Med. 2019;18:1921-1927.
  4. Kawabata T, Tokuda H, Fujita K, Matsushima-Nishiwaki R, Sakai G, Tachi J, Hioki T, Kim W, Iida H, Otsuka T, Kozawa O. HSP90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase. Biomed. Res.-Tokyo. 2019;40:169-178.
  5. Kito Y, Iida M, Tanabe K, Onuma T, Tsujimoto M, Nagase K, Tokuda H, Iwama T, Kozawa O, Iida H.  Smoking cessation affects human platelet activation induced by collagen. Exp Ther Med. 2019;18:3809-3816.
  6. Mizutani D, Onuma T, Tanabe K, Kojima A, Uematsu K, Nakashima D, Doi T, Enomoto Y, Matsushima-Nishiwaki R, Tokuda H, Ogura S, Iida H, Kozawa O, Iwama T. Olive polyphenol reduces the collagen-elicited release of phosphorylated HSP27 from human platelets. Biosci. Biotechnol. Biochem. 2019;24:1-8.

先頭へ戻る

2018年

欧文原著​

  1. Tokuda H, Kuroyanagi G, Onuma T, Enomoto Y, Doi T, Iida H, Otsuka T, Ogura S, Iwama T, Kojima K, Kozawa O. Ristocetin induces phosphorylated-HSP27 (HSPB1) release from the platelets of type 2DM patients: Anti-platelet agent-effect on the release. Biomed. Rep. 2018;8:365-372.
  2. Sable-Morita S, Sugiura S, Uchida Y, Tanikawa T, Tokuda H, Arai H. Relationship between hearing impairment and frailty in older patients with diabetes mellitus. J. Aging Geriatr. Med. 2018;2:1. doi:10.4172/2576-3946.1000114.
  3. Sakai G, Tokuda H, Yamamoto N, Matsushima-Nishiwaki R, Fujita K, Kawabata T, Kozawa O, Otsuka T. Association of HSP22 with mTOR in osteoblasts: regulation of TNF-alfa-stimulated IL-6 synthesis. FEBS Lett. 2018;592:1202-1210.
  4. Fujita K, Otsuka T, Kawabata T, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Inhibitors of heat shock protein 90 (HSP90; HSPC) augment endothelin-1-induced heat shock protein27 (HSP27; HSPB1) through SAPK/JNK in osteoblasts. Mol. Med. Rep. 2018;17:8542-8547.
  5. Fujita K, Otsuka T, Kawabata T, Kainuma S, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. HSP90 limits thrombin-stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells: regulation of p38 MAPK. Int. J. Mol. Med. 2018;42:2185-2192.
  6. Kawabata T, Tokuda H, Sakai G, Fujita K, Matsushima-Nishiwaki R, Otsuka T, Kozawa O. Repression of IGF-I-induced osteoblast migration by (-)-epigallocatechin gallate through p44/p42 MAP kinase signaling. Biomed. Rep. 2018;9:318-326.
  7. Uematsu K, Enomoto Y, Onum T, Tsujimoto M, Doi T, Matsushima-Nishiwaki R, Tokuda H, Ogura S, Iida H, Kozawa O, Iwama T. Rac regulates the TRAP-induced release of phosphorylated-HSP27 from human platelets via p38 MAP kinase but not JNK. Cell. Physiol. Biochem. 2018;49:1523-1538.
  8. Ogama N, Sakujrai T, Kawashima S, Tanikawa T, Tokuda H, Satake S, Miura H, Shimizu A, Kokubo M, Niida S, Toba K, Umegaki H, Kuzuya M. Postprandial hyperglycemia is associated with white matter hyperintensity and brain atrophy in older patients with type 2 diabetes mellitus. Frontiers ㏌ Aging Neuroscience. 2018;10:273.
  9. Kawabata T, Otsuka T, Fujita K, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. (-)-Epigallocatechin gallate but not chlorogenic acid suppresses EGF-stimulated migration of osteoblasts via attenuation of p38 MAPK activity.  Int. J. Mol. Med. 2018;42:3149-3156.
  10. Kawabata T, Tokuda H, Sakai G, Fujita K, Matsushima-Nishiwaki R, Kuroyanagi G, Otsuka T, Kozawa O. HSP70 inhibitor suppresses IGF-I-stimulated migration of osteoblasts through p44/p42 MAP Kinase. Biomedicines. 2018;6(4). pii: E109. doi: 10.3390/biomedicines6040109.
  11. Kawabata T, Otsuka T, Fujita K, Sakai G, Kim W, Matsushima-Nishiwaki R, Kuroyanagi G, Kozawa O, Tokuda H. HSP70 inhibitors reduce the osteoblast migration by epidermal growth factor. Curr. Mol. Med. 2018;18:486-495.

 

 

和文総説

  1. 谷川隆久,徳田治彦：糖尿病と認知症（6-5）糖尿病に合併する認知症の特徴, 医療の広場/公益財団法人 政策医療振興財団, 2018;58(6):6-7.
  2. 川嶋修司,徳田治彦：糖尿病と認知症（6-6）認知症を合併した糖尿病患者の治療の実際, 医療の広場/公益財団法人 政策医療振興財団, 2018;58(7):4-6.

先頭へ戻る

2017年

欧文原著

  1. Kuroyanagi G, Tokuda H, Yamamoto N, Kainuma S, Fujita K, Ohguchi R, Kawabata T, Sakai G, Matsushima-Nishiwaki R, Harada A, Kozawa O, Otsuka T. (-)-Epigallocatechin gallate synergistically potentiates prostaglandin E2-stimulated osteoprotegerin synthesis in osteoblasts. Prostaglandins Other Lipid Mediat. 2017;128-129:27-33.
  2. Fujita K, Tokuda H, Yamamoto N, Kainuma S, Kawabata T, Sakai G, Kuroyanagi G, Matsushima-Nishiwaki R, Harada A, Kozawa O, Otsuka T. Incretins amplify TNF-alfa-stimulated IL-6 synthesis in osteoblasts: Suppression of the IkappaB/NF-kappaB pathway. Int. J. Mol. Med. 2017;39:1053-1060.
  3. Kuroyanagi G, Tokuda H, Yamamoto N, Kainuma S, Fujita K, Ohguchi R, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Attenuation of prostaglandin E1‑induced osteoprotegerin synthesis in osteoblasts by normoxic HIF inducers. Mol. Med. Rep. 2017;15:1847-1852.
  4. Fujita K, Tokuda H, Kuroyanagi G, Yamamoto N, Kainuma S, Kawabata T, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. HSP90 inhibitors potentiate PGF2alfa-induced IL-6 synthesis via p38 MAP kinase in osteoblasts. PLoS One. 2017;12:e0177878.
  5. Onuma T, Tanabe K, Kito Y, Tsujimoto M, Uematsu K, Enomoto Y, Matsushima-Nishiwaki R, Doi T, Nagase K, Akamatsu S, Tokuda H, Ogura S, Iwama T, Kozawa O, Iida H. Sphingosine 1-phosphate (S1P) suppresses the collagen-induced activation of human platelets via S1P4 receptor. Thromb. Res. 2017;156:91-100.
  6. Fujita K, Otsuka T, Yamamoto N, Kainuma S, Ohguchi R, Kawabata T, Sakai G, Kuroyanagi G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. (-)-Epigallocatechin gallate but not chlorogenic acid upregulates osteoprotegerin synthesis through regulation of bone morphogenetic protein-4 in osteoblasts. Exp. Ther. Med. 2017;14:417-423.
  7. Fujita K, Tokuda H, Kainuma S, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Harada A, Kozawa O, Otsuka T. Resveratrol suppresses thyroid hormone‑induced osteocalcin synthesis in osteoblasts. Mol. Med. Rep. 2017;16:2881-2886.
  8. Sakai G, Otsuka T, Fujita K, Kainuma S, Kuroyanagi G, Kawabata T, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Amplification by (‑)‑epigallocatechin gallate of prostaglandin F2alfa‑stimulated synthesis of osteoprotegerin in osteoblasts. Mol. Med. Rep. 2017;16:6376-6381.
  9. Kainuma S, Tokuda H, Yamamoto N, Kuroyanagi G, Fujita K, Kawabata T, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Heat shock protein 27 (HSPB1) suppresses the PDGF-BB-induced migration of osteoblasts. Int. J. Mol. Med. 2017;40:1057-1066.
  10. Kawabata T, Tokuda H, Fujita K, Kainuma S, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Resveratrol inhibits the epidermal growth factor-induced migration of osteoblasts: The suppression of SAPK/JNK and Akt. Cell. Physiol. Biochem. 2017;43:1025-1036.
  11. Kawabata T, Otsuka T, Fujita K, Kainuma S, Yamamoto N, Kuroyanagi G, Sakai G, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Suppression by HSP90 inhibitors of BMP‑4‑stimulated osteoprotegerin synthesis in osteoblasts: Attenuation of p70 S6 kinase. Mol. Med. Rep. 2017;16:8507-8512.
  12. Sakai G, Tokuda H, Fujita K, Kainuma S, Kawabata T, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Heat shock protein 70 negatively regulates TGF-beta-stimulated VEGF synthesis via p38 MAP kinase in osteoblasts. Cell. Physiol. Biochem. 2017;44:1133-1145.

                                                                                                                   先頭へ戻る

2016年

欧文原著

  1. Kuroyanagi G, Otsuka T, Yamamoto N, Kainuma S, Ohguchi R, Fujita K, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Mimosine suppresses the PGF2alfa-induced synthesis of osteoprotegerin but not interleukin-6 in osteoblasts. Int. J. Mol. Med. 2016;37:533-541.
  2. Tsujimoto M, Kuroyanagi G, Matsushima-Nishiwaki R, Kito Y, Enomoto Y, Iida H, Ogura S, Otsuka T, Tokuda H, Kozawa O, Iwama T. Factor Xa inhibitor suppresses the release of phosphorylated HSP27 from collagen-stimulated human platelets: inhibition of HSP27 phosphorylation via p44/p42 MAP kinase. PLoS One. 2016;11:e0149077. 
  3. Kainuma S, Otsuka T, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Regulation by AMP-activated protein kinase of PGE2-induced osteoprotegerin synthesis in osteoblasts. Mol. Med. Rep. 2016;13:3363-3369.
  4. Kainuma S, Otsuka T, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Possible involvement of AMP-activated protein kinase in PGE1-induced synthesis of osteoporotegerin in osteoblasts. Exp. Ther. Med. 2016;11:2042-2048.
  5. Tokuda H, Kuroyanagi G, Tsujimoto M, Matsushima-Nishiwaki R, Akamatsu S, Enomoto Y, Iida H, Otsuka T, Ogura S, Iwama T, Kojima K, Kozawa O. Thrombin receptor-activating protein (TRAP)-activated Akt is involved in the release of phosphorylated-HSP27 (HSPB1) from platelets in DM patients. Int. J. Mol. Sci. 17, 737; doi: 10.3390/i jms17050737,2016
  6. Yamamoto N, Tokuda H, Kuroyanagi G, Kainuma S, Matsushima-Nishiwaki R, Fujita K, Kozawa O, Otsuka T. Heat shock protein 22(HSPB8) limits TGF-beta-stimulated migration of osteoblasts. Mol. Cell. Endocrinol. 2016;436:1-9.
  7. Tsujimoto M, Tokuda H, Kuroyanagi G, Yamamoto N, Kainuma S, Matsushima-Nishiwaki R, Onuma T, Iida Y, Kojima A, Sawada S, Doi T, Enomoto Y, Tanabe K, Akamatsu S, Iida H, Ogura S, Otsuka T, Kozawa O, Iwama T. AICAR reduces collagen-stimulated secretione of PDGF-AB and release of soluble CD40 ligand from human platelets: suppression of HSP27 phosphorylation via p44/p42 MAP kinase. Exp. Ther. Med. 2016;12:1107-1112.
  8. Kainuma S, Tokuda H, Fujita K, Kawabata T, Sakai G, Matsushima-Nishiwaki R, Harada A, Kozawa O, Otsuka T. Attenuation by incretins of thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. Biomed. Rep. 2016;5:771-775.

和文総説

  1. 谷川隆久、荒井秀典：サルコペニア・フレイルの概念, 腎と透析, 2016;80(5):587-590.

著書

  1. 谷川隆久、徳田治彦：今後の展望について（新しい研究、治験など）(3)臨床検査, サルコペニア診療マニュアル, メジカルビュー社, 2016年3月, pp114-120．

先頭へ戻る

2015年

欧文原著

  1. Iida Y, Doi T, Tokuda H , Matsushima-Nishiwaki R, Tsujimoto M, Kuroyanagi G, Yamamoto N, Enomoto Y, Tanabe K, Otsuka T, Iwama T, Ogura S, Kozawa O, Iida H. Rho-kinase regulates human platelet activation induced by thromboxane A2 independently of p38 MAP kinase. Prostaglandins Leukot. Essent. Fatty Acids. 2015;94:73-81.
  2. Tsujimoto M, Doi T, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Iida Y, Enomoto Y, Iida H, Ogura S, Otsuka T, Tokuda H, Kozawa O, Iwama T. Alfa B-crystallin reduces ristocetin-induced soluble CD40 ligand release in human platelets: suppression of thromboxane A2 generation. Mol. Med. Rep. 2015;12:357-362.
  3. Tokuda H, Kuroyanagi G, Tsujimoto M, Enomoto Y, Matsushima-Nishiwaki R, Onuma T, Kojima A, Doi T, Tanabe K, Akamatsu S, Iida H, Ogura S, Otsuka T, Iwama T, Tanikawa T, Ishikawa K, Kojima K, Kozawa O. Release of phosphorylated HSP27 (HSPB1) from platelets is accompanied with the acceleration of aggregation in diabetic patients. PLoS One 2015;10:e0128977.
  4. Kuroyanagi G, Tokuda H, Yamamoto N, Matsushima-Nishiwaki R, Mizutani J, Kozawa O, Otsuka T. Resveratrol amplifies BMP-4-stimulated osteoprotegerin synthesis via p38 MAP kinase in osteoblasts. Mol. Med. Rep. 2015;12:3849-3854.
  5. Yamamoto N, Otsuka T, Kondo A, Matsushima-Nishiwaki R, Kuroyanagi G, Kozawa O,  Tokuda H. Rac limits TGF-beta-induced VEGF synthesis in osteoblasts. Mol. Cell. Endocrinol. 2015;405:35-41.
  6. Kuroyanagi G, Tokuda H , Yamamoto N, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Unphosphorylated HSP27 (HSPB1) regulates the translation initiation process via a direct association with eIF4E in osteoblasts. Int. J. Mol. Med. 2015;36:881-889.
  7. Kuroyanagi G, Otsuka T, Yamamoto N, Matsushima-Nishiwaki R, Kozawa O, Tokuda H. Resveratrol suppresses TGF-beta-induced VEGF synthesis in osteoblasts: inhibition of the p44/p42 MAP kinase and SAPK/JNK pathways. Exp. Ther. Med. 2015;9:2303-2310.
  8. Yamamoto N, Otsuka T, Kuroyanagi G, Kondo A, Kainuma S, Nakakami A, Matsushima-Nishiwaki R, Kozawa O, Tokuda H . Resveratrol reduces prostaglandin E1-stimulated osteoprotegerin synthesis in osteoblasts: Suppression of stress-activated protein kinase/c-Jun N-terminal kinase. Prostaglandins Other Lipid Mediat. 2015;9;116-117:57-63.
  9. Kainuma S, Tokuda H , Kuroyanagi G, Yamamoto N, Ohguchi R, Fujita K, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. PGD2 stimulates osteoprotegerin synthesis via AMP-activated protein kinase in osteoblasts: regulation of ERK and SAPK/JNK. Prostaglandins Leukot. Essent. Fatty Acids. 2015;101:23-29.
  10. Yamamoto N, Tokuda H, Kuroyanagi G, Kainuma S, Ohguchi R, Fujita K, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Amplification by (-)-epigallocatechin gallate and chlorogenic acid of TNF-alfa-stimulated interleukin-6 synthesis in osteoblasts. Int. J. Mol. Med. 2015;36:1707-1712.

和文総説

  1. 谷川隆久、徳田治彦：高齢者におけるリハビリテーションの意義, 第11回　高齢者におけるリハビリテーションの阻害因子とそれに対応する一般的対応 6.糖尿病, Geriat. Med. 2015;53(2):177-181.

先頭へ戻る

2014年以前

欧文原著

  1. Kuroyanagi G, Tokuda H, Matsushima-Nishiwaki R, Kondo A, Mizutani J, Kozawa O, Otsuka T. Resveratrol suppresses prostaglandin F2alfa-induced osteoprotegerin synthesis in osteoblasts: inhibition of the MAP kinase signaling. Arch. Biochem. Biophys. 2014;542:39-45.
  2. Kondo A, Tokuda H, Matsushima-Nishiwaki R, Kuroyanagi G, Yamamoto N, Mizutani J, Kozawa O, Otsuka T. Rho-kinase limits BMP-4-stimulated osteocalcin synthesis in osteoblasts:regulation of the p38 MAP kinase pathway. Life Sci. 2014;96:18-25.
  3. Kondo A, Otsuka T, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Mizutani J, Kozawa O, Tokuda H. Resveratrol inhibits BMP-4-stimulated VEGF synthesis in osteoblasts:suppression of S6 kinase. Int. J. Mol. Med. 2014;33:1013-1018.
  4. Kageyama Y, Doi T, Matsushima-Nishiwaki R, Iida Y, Akamatsu S, Kondo A, Kuroyanagi G, Yamamoto N, Mizutani J, Otsuka T, Tokuda H, Iida H, Kozawa O, Ogura S. Involvement of Rac in thromboxane A2-induced human platelet activation: regulation of sCD40 ligand release and PDGF-AB secretion. Mol. Med. Rep.　2014;10:107-112.
  5. Iida Y, Doi T, Matsushima-Nishiwaki R, Tokuda H, Ogura S, Kozawa O, Iida H. (-)-Epigallocatechin gallate selectively inhibits adenosine diphosphate-stimulated human platelet activation: Suppression of heat shock protein 27 phosphorylation via p38 mitogen-activated protein kinase. Mol. Med. Rep. 2014;10:1383-1388.
  6. Kuroyanagi G, Mizutani J, Kondo A, Yamamoto N, Matsushima-Nishiwaki R, Otsuka T, Kozawa O, Tokuda H. Suppression by resveratrol of prostaglandin D2-stimulated osteoprotegerin synthesis in osteoblasts. Prostaglandins Leukot Essent Fatty Acids. 2014;91:73-80.
  7. Yamamoto N, Tokuda H, Kuroyanagi G, Mizutani J, Matsushima-Nishiwaki R, Kondo A, Kozawa O, Otsuka T. Regulation by reseveratrol of prostaglandin E2-stimulated osteoprotegerin synthssis in osteoblasts. Int. J. Mol. Med. 2014;34:1439-1445.
  8. Kuroyanagi G, Otsuka T, Yamamoto N, Matsushima-Nishiwaki R, Nakakami A, Mizutani J, Kozawa O ,Tokuda H. Downregulation by resveratrol of basic fibroblast growth factor-stimulated osteoprotegerin synthesis through suppression of Akt in osteoblasts. Int. J. Mol. Sci. 2014;15:17886-17900.

和文原著

  1. サブレ森田 さゆり、高梨　早苗、嶋田　佳代子、川嶋　修司、細井　孝之、櫻井　孝、徳田　治彦、    原田　敦：転倒歴のある高齢糖尿病患者の転倒要因の検討, 日本転倒予防学会誌, 2014;1:37-43.

2013年

欧文原著

  1. Kondo A, Tokuda H, Kato K, Matsushima-Nishiwaki R, Kuroyanagi G, Mizutani J, Kozawa O, Otsuka T. Rho-kinase negatively regulates thyroid hormone-stimulated osteocalcin synthesisin osteoblasts. Biochimie. 2013;95:719-724.
  2. Kondo A, Otsuka T, Matsushima-Nishiwaki-R, Kuroyanagi G, Mizutani J, Wada I, Kozawa O, Tokuda H. Inhibition of SAPK/JNK lead to enhanced IL-1-induced IL-6 synthesis in osteoblasts. Arch. Biochem. Biophys. 2013;535:227-233.
  3. Kondo A, Otsuka T, Kato K, Matsushima-Nishiwaki R, Kuroyanagi G, Mizutani J, Tokuda H, Kozawa O. AMP-activated protein kinase regulates thyroid hormone- stimulated osteocalcin synthesis in osteoblasts. Int. J. Mol. Med. 2013;31:1457-1462.
  4. Cuong NT, Doi T, Matsushima-Nishiwaki R, Akamatsu S, Kuroyanagi G, Kondo A, Mizutani J, Wada I, Otsuka T, Tokuda H, Kozawa O, Ogura S. Thrombopoietin amplifies ADP-induced HSP27 phosphorylation in human platelets: Importance of pre-treatment. Int. J. Mol. Med. 2013;31:1291-1297.
  5. Kondo A, Tokuda H, Matsushima-Nishiwaki R, Akamatsu S, Kuroyanagi G, Mizutani J, Fukuoka M, Wada I, Kozawa O, Otsuka T. Unphosphorylated heat shock protein 27 suppresses fibroblast growth factor-2-stimulated vascular endothelial growth factor release in osteoblasts. Mol. Med. Rep. 2013;8:691-695.
  6. Kuroyanagi G, Otsuka T, Kondo A, Matsushima-Nishiwaki R, Mizutani J, Kozawa O, Tokuda H. (-)-Epigallocatechin gallate amplifies interleukin-1-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells. Biochimie 2013;95:1933-1938.
  7. Kageyama Y, Doi T, Akamatsu S, Kuroyanagi G, Kondo A, Mizutani J, Otsuka T, Tokuda H, Kozawa O, Ogura S. Rac regulates collagen-induced HSP27 phosphorylation via p44/p42 MAP kinase in human platelets. Int. J. Mol. Med. 2013;32:813-818.
  8. Kuroyanagi G, Yamada K, Imaizumi T, Mizutani J, Wada I, Kozawa O, Tokuda H, Otsuka T. Leg Iymphedema casued by iliopectineal bursitis associated with destruction of a rheumatoid hip joint. Exp. Ther. Med. 2013;6:887-890.
  9. Sogabe N, Tanabe R, Haraikawa M, Maruoka Y, Orimo H, Hosoi T, Goseki-Sone M, Associations between serum bone-specific alkaline phosphotase activity, biochemical parameters, and functional polymorphisms of the tissue-nonspecific alkaline phosphatase gene in a Japanese population. Asia Pac J Clin Nutr. 2013;22:160-165.
  10. Harawatari M, Tsugawa N, Sogabe N, Tanabe R, Kawamura Y, Okano T, Hosoi T, Goseki-Sone M. Effects of gamma-glutamyl carboxylase gene polymorphism （R325Q） on the association between dietary vitamin K intake and gamma-carboxylation of osteocalcin in young adults. Asia Pac J Clin Nutr. 2013;22:646-654.

著書

  1. 徳田　治彦：臨床検査の考え方　老年医学系統講義テキスト 6章.老年疾患の臨床に必要な基礎知識　日本老年医学会編　西村書店　2013:165-178.
  2. 細井　孝之：骨・運動器系　老年医学系統講義テキスト　5章.臓器の加齢変化と老年疾患の発症　日本老年医学会編 西村書店 2013;148-151.
  3. 細井　孝之：骨折リスクとその評価ならびに薬物治療の開始基準　前立腺癌と男性骨粗鬆症 最新骨管理マニュアル　1.男性骨粗鬆症の診療 医学図書出版株式会社 細井孝之、松島常編　2013;36-43.
  4. 細井　孝之：骨粗鬆症治療剤の特徴と男性骨粗鬆症におけるエビデンス i.デノスマブ　前立腺癌と男性骨粗鬆症 最新骨管理マニュアル　1.男性骨粗鬆症の診療　細井孝之、松島常編　医学図書出版株式会社　2013;66-70.
  5. 細井　孝之：前立腺がんと男性骨粗鬆症　最新　骨管理マニュアル　3.ステロイド性骨粗鬆症の特徴と管理　細井孝之、松島常編　医学図書出版株式会社　2013;131-135.

和文総説

  1. 細井　孝之：1.　概論　骨粗鬆症の予防と治療ガイドラインの概要　最新の骨粗鬆症学　骨粗鬆症の最新知見　株式会社日本臨床社　2013;71:21-27.
  2. 細井　孝之：10.骨粗鬆症の類縁疾患の診断と治療　骨粗鬆症・偽神経膠腫症候群　最新の骨粗鬆症学　骨粗鬆症の最新知見　株式会社日本臨床社　2013;71:613-615.
  3. 細井　孝之：第2章　代謝性骨疾患　第2節　臨床知識―骨粗鬆症 3.診断　副甲状腺・骨代謝疾患　診療マニュアル診断と治療 2013;120-121.
  4. 細井　孝之：特集　骨粗鬆症診療の進歩 2011年ガイドラインからみた原発性骨粗鬆症の診断と治療 リウマチ科　科学評論社　2013;49:262-267.
  5. 細井　孝之：骨折予防を目指した積極的な骨粗鬆症診療　Special Article　骨折の一次予防を目指　した治療戦略　内科　南光堂　2013;111:613-617.
  6. 細井　孝之：特集　骨粗鬆症における骨折の連鎖とその予防 健診・検診をいかに取り入れるか　整形・災害外科 金原出版株式会社 2013;56:369-373.
  7. 細井　孝之：特集　高齢者の栄養に対する新しい考え方　Seminar 4.骨粗鬆症・骨代謝と栄養 Geriatric Medicine　株式会社ライフサイエンス　2013;51:403-407.
  8. 細井　孝之：骨粗鬆症の予防と治療ガイドライン2011年版 日本老年医学会雑誌　2013;50:125-129.
  9. 若松俊孝、村崎明広、鈴木笑美子、金子康彦、櫻井孝、細井孝之：認知症における低栄養改善を指標とした栄養食事指導に関する研究。静脈経腸栄養 2013;28:418.
  10. 細井　孝之：特集　実地医家のための臨床栄養　update　高齢者の食・栄養の問題と対応　日本　医師会雑誌　日本医師会　2013;142:268-272.
  11. 細井　孝之：Q5.骨量の減少が気になります。どのくらいで病院へかかるべきですか？ からころ 株式会社ネグジット総研 2013;7:33.
  12. 細井　孝之：Q6.骨密度が低く、エビスタ錠を処方されたが改善せず、エディロールカプセルが追加されました。そのときから便秘が始まり、桃核承気湯を併用していますが、思うように便通がなく毎日たいへんです。適切な処置は？からころ 株式会社ネグジット総研 2013;7:30.
  13. 細井　孝之：Seminar 4.骨粗鬆症・骨代謝と栄養 Geriatric Medicine 株式会社ライフサイエンス 2013;51:403-407.
  14. 細井　孝之：どこでもできるスクリーニング方法 実験治療 武田薬品工業株式会社 2013;709:9-12.
  15. 細井　孝之：最新　研究情報 大腿骨近位部骨折はやはり心筋梗塞の危険因子 Aging&Health　公益財団法人長寿科学振興財団2013;65:4.
  16. 細井　孝之：高齢者の食・栄養の問題と対応 日本医師会雑誌 2013;142:268-272.
  17. 細井　孝之：Q2 骨量と骨密度の違いはどこにあるのでしょうか？　からころ　株式会社ネグジット　総研　2013;7:36.
  18. 細井　孝之、岡野浩哉、古谷武文、浦野友彦：特別　座談会　骨粗鬆症-最新の診断と治療　Vita BML　2013;30:1-18.

2012年

欧文原著

  1. Kato K, Otsuka T, Kondo A, Matsushima-Nishiwaki R, Natsume H, Kozawa O, Tokuda H. AMP-activated protein kinase regulates PDGF-BB-stimulated interleukin-6 synthesis in osteoblasts: involvement of mitogen-activated protein kinase. Life Sci. 2012;90:71-76.
  2. Terabe Y, Harada A, Tokuda H, Okuizumi H, Nagaya M, Shimokata H. Vitamin D deficiency in elderly women in nursing homes : Investigation with consideration of decreased activation function from the kidneys.J. Am. Geriatr. Soc. 2012;60:251-255.
  3. Mizutani J, Tokuda H, Matsushima-Nishiwaki R, Kato K, Kondo A, Natsume H, Kozawa O, Otsuka T. Involvement of AMP-activated protein kinase in TGF-beta-stimulated VEGF synthesis in osteoblasts. Intern. J. Mol. Med. 2012;29:550-556.
  4. Kato K, Tokuda H, Matsushima-Nishiwaki R, Natsume H, Kondo A, Ito Y, Kozawa O, Otsuka T. AMPK limits IL-1-stimulated IL-6 synthesis in osteoblasts: involvement of IkappaB/NF-kappaB pathway. Cell. Signal. 2012;24:1706-1712.
  5. Kondo A, Tokuda H, Mizutani J, Matsushima-Nishiwaki R, Kozawa O, Otsuka T. Wnt3a up-regulates prostaglandin F2alfa-stimulated vascular endothelial growth factor synthesis in osteoblasts. Mol Med Report. 2012;6:421-425.
  6. Tokuda H, Kato K, Natsume H, Kondo A, Kuroyanagi G, Matsushima-Nishiwaki R, Ito Y, Otsuka T, Kozawa O. Involvement of AMP-activated protein kinase in thrombin-stimulated interleukin-6 synthesis in osteoblasts. J. Mol. Endocrinol. 2012;49:47-55.
  7. Doi T, Tokuda H, Matsushima-Nishiwaki R, Cuong NT, Kageyama Y, Iida Y, Akamatsu S, Otsuka T, Iida H, Kondo A, Kozawa O, Ogura S. Effect of antithrombin III on glycoprotein Ib/IX/V activation in human platelets: suppresion of thromboxane A2 generation. Prostaglandins Leukot. Essent. Fatty Acids 2012;87:57-62.
  8. Tokuda H, Kato K, Kasahara S, Matsushima-Nishiwaki R, Mizuno T, Sakakibara S, Kozawa O. Significant correlation between the acceleration of platelet aggregation and phosphorylation of HSP27 at Ser-78 in diabetic patients. Intern. J. Mol. Med 2012;30:1387-1395.
  9. Kondo A, Otsuka T, Kenji K, Natsume H, Kuroyanagi G, Mizutani J, Ito Y, Matsushima -Nishiwaki R, Kozawa O, Tokuda H. AMP-activated protein kinase inhibitor decreases prostaglandin F2alfa-stimulated interleukin-6 synthesis through p38 MAP kinase in osteoblasts.Intern. J. Mol. Med. 2012;30:1487-1492.
  10. Koudu Y, Onouchi T, Hosoi T, Horiuchi T. Association of CYP19 Gene Polymorphism with Vertebral Fractuers in Japanese Postmenopausal woman. Biochem Genet. 2012;50: 389-396.
  11. Haraikawa M, Tanabe R, Sogabe N, Sugioto A, Kawamura Y, michigami T, Hosoi T, Goseki-Sone M. A study the assosiation between Serum Bone-Specific Alkaline Phosphatase and serum Phosphorus Intake. J Nutr Sci vitaminal. 2012;58:442-445.
  12. Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Seno S, Nisizawa Y, Hagino H, Fukunaga M, Fujiwara S. Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos.2012;7:3-20.
  13. Sogabe N, Tanabe R, Haraikawa M, maruoka Y, Orimo H, Hosoi T, Goseki-Sone M. Associations between serum bone-specific alkaline phosphatase acivity, biochemical parameters, and functional polymorphisms of the tissue-nonspecific alkaline phosphatase gene in a Japanese population. Asia Pacific Journal of Clinical Nutrition. 2013;22(1):160-165.
  14. Hosoi T. Calsium-sensing Receptor Antagonist for Psteoporosis.OSTEOPOROSIS. 2013; 9(4):61-70.

和文原著

  1. 亀井智子、藤原佳典、細井孝之、深谷太郎、野中久美子、小池高史、渡邉麗子、澤登久雄、松本真澄、渡辺修一郎、田中千晶：独居認知症高齢者へのSmart home利用の包括的アセスメント評価枠組みの開発-文献レビューと介入研究事例の統合から-聖路加看護大学紀要 2013; No.39.

著書

  1. 細井　孝之：第1章　高齢者に多い疾患に対する薬の使い方1）骨粗鬆症（Q13～Q16） 高齢者の薬よろずお助けQ&A100 羊土社 2012;39-50.

和文総説

  1. 徳田治彦：マーカーによる骨粗鬆症検診の有用性　Osteoporosis Japan. 2012;20:94-98.
  2. 細井　孝之：O．Li．V．E．-骨代謝と生活習慣病の連関-メジカルビュー社 2012；Vol.2：20-25.
  3. 細井　孝之：特集　骨粗鬆症の薬物療法の新戦略アレンドロネート　関節外科　基礎と臨床　メジカルビュー社2012；Vol.31,No.6：48-52.
  4. 細井　孝之：19　骨粗鬆症M.P実地医家のための臨床検査のすすめかた・評価のしかた 文光堂 2012；Vol.29：252-256.
  5. 細井　孝之：2.運動器の評価　2.ロコモの疑いの人の診察法　3）主な疾患の診断と保存治療　（8）骨粗鬆症　ロコモティブ　シンドローム　メジカルビュー社 2012；167-175.
  6. 細井　孝之：2.病態・疾患別のガイドライン　代謝性骨疾患1（骨粗鬆症）骨粗鬆症の評価・治療指針　運動器診療　最新ガイドライン　総合医学社 2012；182-187.
  7. 細井　孝之：第4章　ロコモティブシンドロームと遺伝子多型性　ロコモティブシンドロームと栄養　建帛社 2012；55-64.
  8. 細井　孝之：骨粗鬆症　青淵　公益財団法人 渋沢栄一記念財団 2012；No.755：14-16.
  9. 細井　孝之：骨粗鬆症の予防と治療ガイドライン2011年版Ortho community 2012 メジカルビュー社2012；No.43：11-12.
  10. 細井　孝之：骨粗鬆症の薬物治療開始基準 -骨粗鬆症の予防と治療ガイドライン2011年版から　日本女性医学学会ニューズレター　一般社団法人　日本女性医学学会 2012；Vol.18,No.1：5.
  11. 細井　孝之：臨床　骨折リスク評価ツール「FRAX」の日本人への応用　ORTHO－VIEWS 2012；No.15：6-7.
  12. 細井　孝之：特集　骨粗鬆症診療に関する新しい展開　骨粗鬆症治療における薬物治療介入の ポイント（2011年改訂版ガイドラインの考え方）　内分泌・糖尿病・代謝内科 科学評論社 2012； Vol.34,No.5：410-414.
  13. 細井　孝之：5.特集　骨粗鬆症治療薬のBreakthrough-ガイドライン2011年版を踏まえてー骨折 リスク評価の実際とFRAX MEDICINAL　医学出版2012；Vol.2,No.8：43-48.
  14. 細井　孝之：特集：知っておきたい最新骨粗鬆症診療マニュアル骨折危険因子からOrthopaedics 全日本病院出版会 2012.5；Vol.25,No.5:25-30.
  15. 細井　孝之：マンスリーレクチャー老年内科　標榜をめざして 週刊　日本医事新報 日本医事新報社2012;No.4605 :41-45.
  16. 細井　孝之：骨粗鬆症の治療-新たな薬物治療開始基準 CLINICIAN運動器の10年 エーザイ株式会社2012;Vol.59,No.610:38-43.
  17. 細井　孝之：特集：骨密度測定の再考ＭＤ法（最新の＋DIPシステムについて） 骨粗鬆症治療 先端医学社2012; Vol.11,No.1: 14-18.
  18. 細井　孝之：特集：「骨粗鬆症の予防と治療ガイドライン2011年版」を踏まえた今後の骨粗鬆症治療 骨粗鬆症治療 先端医学社 2012;Vol.10,No.4:10-14.
  19. 細井　孝之：特集：変わる骨粗鬆症治療-内科医が知っておきたい最新トピックから基本的知識まで-骨粗鬆症の予防と治療ガイドライン2011年版 Mebioメジカルビュー社2012.Vol.29,No.5: 41-46.
  20. 細井　孝之：6　骨粗鬆症の治療 2.骨粗鬆症の治療薬 6）その他（カルシトニン、ビタミンK，イプリフラボン）骨粗鬆症診療ハンドブック改訂5版 医薬ジャーナル社 2012; 320-330
  21. 細井　孝之：「ロコモ」への入り口「サルコペニア」とは？Healith&Beauty Review講談社 2012; Vol.29 :64-67.
  22. 細井　孝之：4.骨粗鬆症　4.1骨粗鬆症の概念と分類 高齢者用食品の開発と展望 株式会社シーエムーシー出版 2012; 23-28.
  23. 細井　孝之：特集「骨粗鬆症の予防と治療ガイドライン2011」をめぐってFRAXのわが国での活用 CLINICIAN　CALCIUM 医薬ジャーナル社 2012;Vol.22,No.6: 73-79.
  24. 細井　孝之：特集：アクティブシニアの抗ロコモ骨の加齢性変化と栄養ケア FOOD STYLE21食品化 学新聞社　2012:Vol.16,No.9:31-33.
  25. 杉本利嗣、竹内靖博、荻野浩、宗圓聰、細井　孝之：骨粗鬆症の予防と治療ガイドライン2011年版 をめぐって　Osteoporosis Japan　ライフサイエンス出版株式会社　2012;Vol.20,No.1:5-8.
  26. 細井　孝之：シリーズ　よく使う日常治療薬の正しい使い方 骨粗鬆症に対する薬の使い方レジデントノート 株式会社羊土社　 2012.;Vol.14,No.10: 1927-1930.
  27. 細井　孝之：骨粗鬆症検診の現状と課題 A-TOP　NEWS A-TOP 研究会ニュース 2012; Voｌ.3、No.4: 1-5.
  28. 細井　孝之：A.骨粗鬆症の評価と指針1.「骨粗鬆症の予防と治療ガイドライン2011年版」の概要とおもな改訂点 新しい骨粗鬆症治療 診断と治療社 2012;2-4.
  29. 細井　孝之：骨折リスクに基づいた骨粗鬆症の診断と対策の実際　既存骨折と骨折リスクM.P. 骨粗鬆症の実地診療　up to date　文光堂2012; Vol29,No.1:1886-1890.
  30. 細井　孝之：巻頭連載　目で見るBone Biology骨粗鬆症治療 最先端医学社2012;Vol.11,No.4: 237-240.
  31. 細井　孝之：ロコモティブシンドロームの予防と骨粗鬆症 日本未病システム学会2012;Vol.18,No.3: 74-78.
  32. 細井　孝之：最新　骨祖しょう症対策NHK今日の健康　健康ダイアリー2013年度版株式会社　主婦と生活 2012;152.
  33. 細井　孝之：骨をつくる注射で、骨粗しょう症対 策週１回の注射薬　テリボン 旭化成ファーマ株式会社2012;1-14.
  34. 細井　孝之、黒田龍彦、中村利孝、白木正孝、太田博明、原田敦、森聖二郎、大橋靖雄、折茂肇：全国データベースを用いた骨粗鬆症性骨折の予防と治療に関する研究　Osteoporosis Japan　ライ フサイエンス出版株式会社　2012; Vol.20,No.4: 41-48.
  35. 宗圓聰、福永仁夫、杉本利嗣、曽根照喜、細井　孝之：診断基準の改定に向けてー骨粗鬆症診療の新たな展開をめざしてOsteoporosis Japanライフサイエンス出版株式会社 Vol.20,No.4: 9-12.
  36. 細井　孝之：第13章　骨・運動器疾患 標準理学療法学・作業療法学専門基礎分野　老年学　第3版 医学書院 2012; 146-158.
  37. 細井　孝之：2.慢性合併症　6.骨病変 糖尿病診療ハンドブック 中外医学社 2012;205-211.
  38. 細井　孝之：骨粗鬆症検診の活用 治療 南山堂 2012; Vol.94,No.12: 2001-2005.
  39. 細井　孝之：骨を健康に保つ　骨粗鬆症の予防 へるすあっぷ21株式会社法研 2012; No.328: 46-51.
  40. 細井　孝之：第1回　骨粗鬆症マネージャーレクチャーコース保健師さんの活躍に期待　月刊　地域保健　株式会社東京法規出版 2013; Vol.44,No.1:70-71.
  41. 細井　孝之：特集　老化と生体運動機能 骨粗鬆症に対するアプローチ CLINCAL CALCIUM 医薬ジャーナル社 2013;vol.23,No.1: 75-82.
  42. 細井　孝之：5.転倒と骨折Japanese Journal of Geriatrics社団法人日本老年医学会 2012; Vol.49, Supplement.
  43. 野中久美子、小池高史、渡邊麗子、深谷太郎、渡辺修一郎、松本真澄、田中千晶、植木章三、 細井孝之、藤原佳典：自立支援機器を用いた地域包括システムの開発-（2）地域ケア機関が抱える課題 Japanese Journal of Geriatrics社団法人日本老年医学会 2012; Vol.49,Supplement: 126.
  44. 渡邊麗子、野中久美子、小池高史、深谷太郎、渡辺修一郎、松本真澄、田中千晶、植木章三、細井孝之、藤原佳典：自立支援機器を用いた地域包括システムの開発ー（3）自立支援機構器の設置可否に影響する要因　Japanese Journal of Geriatrics　社団法人日本老年医学会　2012; Vol.49, Supplement: 126.
  45. 細井　孝之：各論　薬物療法Osteoporosis Japan　ライフサイエンス出版株式会社　2012;Vol.21,No.1: 138-139.
  46. 宗圓聰、福永仁夫、杉本利嗣、曽根照喜、藤原佐枝子、遠藤直人、五夾逸雄、白木正孝、荻野浩、細井孝之、太田博明、米田俊之、友光達志：原発性骨粗鬆症の診断基準（2012年度改訂版）Osteo porosis Japanライフサイエンス出版株式会社 2012;Vol.21,No.1: 9-21.
  47. 細井　孝之：転倒と骨折 日本老年医学会雑誌 2012; Vol.50,No.1:36-39. 細井孝之、中藤真一: 地域・社会における骨粗鬆症ー骨粗鬆症リエゾンサービスとFRAXの活用 O．LI．V．E．-骨代謝と生活習慣病の連関- メディカルレビュー社2013; Vol.3,No1: 48-50.
  48. 細井　孝之：サルコペニアにおけるビタミンDの意義 栄養・運動で予防するサルコペニア 医歯薬出版株式会社 2013; 122-127.
  49. 細井　孝之：特集　骨粗鬆症治療の新展開 10．骨粗鬆症治療薬の継続と服薬管理 医薬ジャーナル2013; Vol.49,No.3: 137-140.
  50. 川嶋　修司 ：[症候と疾患から迫る！ERの感染症診療　疑い、探し、組み立てる実践的な思考プロセス]（第2章）原因疾患へのアプローチ　ＥＲでの腹腔内感染症　胆管炎　胆嚢炎　（解説/特集）　レジデントノート別冊救急・ERノート2012；Vol.6,205-210.

2011年

欧文原著

  1. Natsume H, Tokuda H, Adachi S, Matsushima-Nishiwaki R, Kato K, Minamitani C, Mizutani J, Otsuka T, Kozawa O. Wnt3a regulates tumor necrosis factor-α-stimulated interleukin-6 release in osteoblasts. Mol.Cell. Endocrinol. 2011; 331: 66-72.
  2. Kato K, Tokuda H, Adachi S, Matsushima-Nishiwaki R, Yamauchi J, Natsume H, Minamitani C, Mizutani J, Otsuka T, Kozawa O. Role of heat shock protein 27 in transforming growth factor-β-stimulated vascular endothelial growth factor release in osteoblasts. Int.J.Mol.Med. 2011; 27: 423-428.
  3. Kato K, Otsuka T, Adachi S, Matsushima-Nishiwaki R, Natsume H, Kozawa O, Tokuda H. （-）-Epigallocatechin gallate inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. Mol.Med.Rep. 2011; 4: 297-300.
  4. Kato K, Adachi S, Matsushima-Nishiwaki R, Minamitani C, Natsume H, Mizutani J, Tokuda H, Kozawa O, Otsuka T. Regulation by heat shock protein 27 of osteocalcin synthesis in osteoblasts. Endocrinology. 2011; 152: 1872-1882.
  5. Enomoto Y, Adachi S, Doi T, Natsume H, Kato K, Matsushima-Nishiwaki R, Akamatsu S, Tokuda H, Yoshimura S, Otsuka T, Ogura S, Kozawa O, Iwama T. cAMP regulates ADP-induced HSP27 phosphorylation in human platelets. Int.J.Mol.Med. 2011; 27: 695-700.
  6. Tokuda H, Adachi S, Matsushima-Nishiwaki R, Kato K, Natsume H, Otsuka T, Kozawa O. Enhancement of basic fibroblast growth factor-stimulated VEGF synthesis by Wnt3a in osteoblasts. Int.J.Mol.Med. 2011; 27: 859-864.
  7. Natsume H, Tokuda H, Matsushima-Nishuwaki R, Kato K, Yamakawa K, Otsuka T, Kozawa O. Wnt3a up-regulates transforming growth factor-beta-stimulated VEGF synthesis in osteoblasts. Cell.Biochem Funct. 2011; 29: 371-377.
  8. Kato K, Otsuka T, Matsushima-Nishiwaki R, Natsume H, Kozawa O, Tokuda H. Rho-kinase regulates thrombin-stimulated interleukin-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. Int.J.Mol.Med. 2011; 28: 653-658.
  9. Kato K, Tokuda H, Mizutani J, Adachi S, Matsushima-Nishiwaki R, Natsume H, Kozawa O, Otsuka T. Role of HSP27 in tumor necrosis factor-alfa-stimulated interleukin-6 synthesis in osteoblasts. Int. J. Mol. Med. 2011; 28: 887-893.
  10. Haraikawa M, Sogabe N, Tanabe R, Hosoi T, Goseki-Sone M. Vitamin K1　（Phylloquinone） or Vitamin K2 （Menaquinone-4） Induces Intestinal Alkaline Phosphatase Gene Expression. J　Nutr　Vitaminol. 2011; 57: 274-279.
  11. Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A, Tanaka S, Tanaka T, Hosoi T, Itoi E, Morimoto S, Itabashi A, Sugimoto T, Yamashita T, Gorai I, Mori S, Kishimoto H, Mizunuma H, Endo N, Nishizawa Y, Takaoka K, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H. Desigh of pragmatic approach to evaluate the effectivenss of concurrent treatment for the prevention of osteoporotic fractures. J. Bone and Mineral Metab. 2011; 29: 37-43.

著書

  1. 細井孝之："第1編　骨と軟骨 第1章　骨粗鬆症" 機能性食品素材の骨と軟骨への応用 2011; 3-10.
  2. 細井孝之：1.骨の健康と骨粗鬆症の予防 チームで学ぶ乳癌の骨マネジメント 2011; 3-14.
  3. 細井孝之：骨代謝異常　骨代謝総論 病気がみえる3　糖尿病・代謝・内分泌 2011; 130-141.

和文総説

  1. 細井孝之：8.薬物による治療効果の評価-現状と問題点- THE　BONE 2011; 25: 63-67
  2. 細井孝之：新薬展望2011 第3部　治療における最近の新薬の位置付け<薬効別>～新薬の広場～骨粗鬆症治療薬 医薬ジャーナル　新薬展望　2011（増刊号） 2011; 47: 263-269.
  3. 細井孝之：特集：生活習慣病をめぐる最近の課題-産婦人科医に必要な知識- 食生活と骨粗鬆症 産婦人科治療 2011; 102: 96-100.
  4. 細井孝之：骨折リスクの評価方法：FRAXとOSTA BONE CARE 2011; 11: 5.
  5. 細井孝之：栄養介入によるサルコペニア予防・治療の可能性 モダンフィジャン 2011; 31: 1362-1366.
  6. 細井孝之：特集：生活習慣病関連骨粗鬆症の病態と管理・治療戦略 遺伝要因からみた生活習慣病と骨粗鬆症との関連 MEDICINAL 2011; 1: 56-60.
  7. 細井孝之：第3章 骨粗鬆症の予防と治療ガイドライン（2011年改訂版）について 日経メディカル 2011; 2: 97-98.
  8. 細井孝之：3.臨床編　認知症の重症化に伴う医学的諸問題　各論 h.転倒と骨折 日本臨床 増刊号 認知症学（下） 2011; 69: 544-551.
  9. 細井孝之：骨粗鬆症 medicina 2011; 48: 593-596.
  10. 細井孝之：ガイドラインにおける骨粗鬆症薬物治療開始基準変更点-FRAXの位置づけを踏まえて- SERM 2011; 9: 92.
  11. 細井孝之：骨粗鬆症の診断基準と薬物療法の開始の目安 Geriatric Medicine 2011; 49: 963-966.
  12. 細井孝之：骨粗鬆症と生活習慣 診断と治療 2011; 99: 1673-1678.
  13. 細井孝之：骨粗鬆症 JOURNAL OF THE JAPAN DIETETIC ASSOCIATION 2011; 54: 8-12.
  14. 細井孝之：質疑応答 週刊 日本医事新報 2011; 4561: 50-51.
  15. 山内広世、佐々木利幸、細井孝之：特集：骨粗鬆症　7.骨粗鬆症の予防法 骨粗鬆症健診の現状 日本臨牀 2011; 69: 1300-1304.
  16. 細井孝之：老年期における骨粗鬆症の予防 オステオポローシス　ジャパン 2011; 19: 364-367.
  17. 細井孝之：骨粗鬆症の予防と治療ガイドラインにおける薬物治療開始基準変更の意義 週刊 日本医事新報 2011; 4586: 50-51.
  18. 細井孝之：今月の主題　臨床栄養Update 2011 各疾患の病態別栄養評価と栄養療法【内分泌・代謝疾患】骨粗鬆症 medicina 2011; 48: 427-430.

2010年

欧文原著

  1. Tokuda H, Adachi S, Matsushima-Nishiwaki R, Hanai Y, Takai S, Harada A, Kozawa O. Inhibition by minodroate of basic fibroblast growth factor-stimulated vasucular endothelial growth factor synthesis in osteoblast-like cells. Mol. Med. Rep. 2010；3:167-171.
  2. Takai S, Tokuda H, Matsushima-Nishiwaki R, Saio M, Takami T, Kozawa O. TGF-β superfamily enhances the antigen-induced IFN-γ production by effector/memory CD8+ T cells. Intern. J. Mol. Med. 2010;25:105-111.
  3. Tokuda H, Harada A, Adachi S, Matsushima-Nishiwaki R, Natsume H, Minamitani C, Mizutani J, Otsuka T, Kozawa O. Raloxifene enhances spontaneous microaggregation of platelets through upregulation of p44/p42 MAP kinase: a case report. Osteoporos Int. 2010;21:189-193.
  4. Natsume H, Tokuda H, Adachi S, Takai S, Matsushima-Nishiwaki R, Kato K, Minamitani C, Niida S, Mizutani J, Kozawa O, Otsuka T. Rho-kinase limits FGF-2-stimulated VEGF release in osteoblasts. Bone. 2010;46:1068-1074.
  5. Minamitani C, Tokuda H, Adachi S, Matsushima-Nishiwaki R, Yamauchi J, Kato K, Natsume H, Mizutani J, Kozawa O, Otsuka T. p70 S6 kinase limits tumor necrosis factor-α-induced interleukin-6 synthesis in osteoblast-like cells. Mol. Cell. Endocrinol. 2010;315:195-200.
  6. Enomoto Y, Adachi S, Matsushima-Nishiwaki R, Doi T, Niwa M, Akamatsu S, Tokuda H, Ogura S, Yoshimura S, Iwama T, Kozawa O. Thromboxane A2 promotes soluble CD40 ligand release from human platelets. Atherosclerosis. 2010;209:415-421.
  7. Kato H, Adachi S, Doi T, Matsushima-Nishiwaki R, Minamitani C, Akamatsu S, Enomoto Y, Tokuda H, Otsuka T, Iwama T, Kozawa O, Ogura S. Mechanism of collagen-induced release of 5-HT, PDGF-AB and sCD40L from human platelets: Role of HSP27 phosphorylation via p44/p42 MAPK. Thrombosis Res. 2010;126:39-43.
  8. Natsume H, Tokuda H, Mizutani J, Adachi S, Matsushima-Nishiwaki R, Minamitani C, Kato K, Kozawa O, Otsuka T. Synergistic effect of vasoactive intestinal peptides on TNF-α-induced IL-6 synthesis in osteoblasts: amplification of p44/p42 MAP kinase activation. Intern. J. Mol. Med. 2010;25:813-817.
  9. Kato K, Tokuda H, Natsume H, Adachi S, Matsushima-Nishiwaki R, Minamitani C, Mizutani J, Kozawa O, Otsuka T. Rho-kinase regulates prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts. Exp. Therapeut. Med. 2010;1:579-583.
  10. Doi T, Adachi S, Matsushima-Nishiwaki R, Kato H, Enomoto Y, Natsume H, Kato K, Mizutani J, Otsuka T, Tokuda H, Akamatsu S, Iwama T, Kozawa O, Ogura S. Antithrombin III reduces collagen-stimulated granule secretion of PDGF-AB and the release of soluble CD40 ligand from human platelets. Intern. J. Mol. Med. 2010;26:387-392.
  11. Kato K, Tokuda H, Adachi S, Matsushima-Nishiwaki R, Natsume H, Yamakawa K, Gu Y, Otsuka T, Kozawa O. AMP-activated protein kinase positively regulates FGF-2-stimulated VEGF synthesis in osteoblasts. Biochem. Biophys. Res. Commun. 2010;400:123-127.
  12. Hosoi T. Genetic aspects of osteoporosis. J Bone Miner Metab. 2010；228（6）:601-607.
  13. Urano T, Narusawa K, Kobayashi S, Shiraki M, Horie-Inoue K, Sasaki N, Hosoi T, Ouchi Y, Nakamura T, Inoue S. Association of HTRA1 pormoter polymorphism with spinal disc degeneration in Japanese women. J Bone Miner Metab. 2010;28（2）:220-226.
  14. Urano T, Narusawa K, Shiraki M, Sasaki N, Hosoi T, Ouchi Y, Nakamura T, Inoue S.Single-nucleotide polymorphism in the hyaluronan and proteoglycan link protein 1 （HAPLN1） gene is associated with spinala osteophyte formation and disc degeneraton in Japanese women. Eur Spine J. Epub　2010 Oct 15.
  15. Tanaka S, Yoshimura N, Kuroda T, Hosoi T, Saito M, Shiraki M. The Fracture and immobilization Score （FRISC） for risk assessment of osteoporotic fracture and immobilization in postmenopausal women-A joint analysis of the Nagano, Miyama, and Taiji Cohorts.Bone. 2010;47（6）:1064-1070.
  16. Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A, Tanaka S, Tanaka Y, Hosoi T, Itoi E, Morimoto S, Itabashi A, Sugimoto T, Yamashita T, Gorai I, Mori S, Kishimoto H, Mizunuma H, Endo N, Nishizawa Y, Takaoka K, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H. Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: Rationale, aims and organization of a Japanese Osteoporosis Intervention Trial （JOINT） initiated by the Research Group of Adequate Treatment of Osteoporosis （A-TOP） J Bone Miner Metab. 2010 May 13.
  17. Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatmet.J Bone Miner Metab. 2010;28（5）:578-584.
  18. Mori S, Fuku N, Chiba Y, Tokimura F, Hosoi T, Kimbara Y, Tamura Y, Araki A, Tanaka M, Ito H. Cooperative effects of serum 25-hydroxyvitamin D concentration and a polymorphism of transforming growth factor-beta 1 gene on the prevalence of vertebral fractures in postmenopausal osteoporosis. J Bone Miner Metab. 2010;28（4）:446-450.

2009年

欧文原著

  1. Kuno M, Takai S, Matsushima-Nishiwaki R, Minamitani C, Mizutani J, Otsuka T, Harada A, Adachi S, Kozawa O, Tokuda H. Rho-kinase inhibitors decrease TGF-β-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Biochem Pharmacol. 2009；77:196-203.
  2. Tokuda H, Hosoi T, Hayasaka K, Okamura K, Yoshimi N, Kozawa O. Overexpresion of protein kinase C-δ plays a crucial role in interleukin-6-producing pheochromocytoma presenting with acute inflammatory syndrome: A case report. Horm. Metab. Res. 2009；41:333-338.
  3. Yamauchi J, Takai S, Matshushima-Nishiwaki R, Adachi S, Minamitani C, Natsume H, MizutaniJ, Otsuka T, Takeda J, Harada A, Kozawa O, Tokuda H. Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts. Intern. J. Mol. 2009；23:267-272.
  4. Minamitani C, Otsuka T, Takai S, Matsushima-Nishiwaki R, Adachi S, Hanai Y, Mizutani J, Tokuda H, Kozawa O. Involvement of Rho-kinase in sphingsine 1-phosphate-stimulated HSP27 induction in osteoblasts. Intern. J. Mol. Med. 2009；24:77-82.
  5. Natsume H, Mizutani J, Adachi S, Matsushima-Nishiwaki R, Minamitani C, Tokuda H, Kozawa O, Otsuka T. Involvement of Rho-kinase in TGF-β-stimulated heat shock protein 27 induction in osteoblasts. Mol. Med. Reports. 2009；2:687-691.
  6. Natsume H, Adachi S, Takai S, Tokuda H, Matsushima-Nishiwaki R, Minamitani C, Yamauchi J, Kato K, Kozawa O. （-）-Epigallocatechin gallate attenuates the induction of HSP27 stimulated by sphingosine 1-phosphoate via suppression pf phosphatidylinositol 3-kinase/Akt pathway in osteoblasts. Intern. J. Mol. Med. 2009；24:197-203.
  7. Adachi S, Tokuda H, Matsushima-Nishiwaki R, Kato K, Natsume H, Minamitani C, Mizutani J, Otsuka T, Kozawa O. Involvement of Rho-kinase in prostaglandin E1-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblast like MC3T3-E1 cells. Prostaglandins Other Lipid Mediat. 2009；90:1-6.
  8. Enomoto Y, Adachi S, Matsushima-Nishiwaki R, Niwa M, Tokuda H, Akamatsu S, Doi T, Kato H, Yoshimura S, Ogura S, Iwama T, Kozawa O.αB-crystalin extracellularly suppresses ADP-induced granule secretion from human platelets. FEBS Lett. 2009；583:2464-2468.
  9. Hanai Y, Adachi S, Yasuda I, Takai S, Matsushima-Nishiwaki R, Kato H, Enomoto Y, Akamatsu S, Sakakibara S, Ogura S, Iwama T, Kozawa O, Tokuda H. Collagen-induced p38 MAP kinase activation is a biomarker of platelet hyper-aggregation in patients with diabetes mellitus. Life Sci. 2009;85:386-394.
  10. Doi T, Adachi S, Takai S, Matsushima-Nishiwaki R, Kato H, Enomoto Y, Minamitani C, Otsuk T, Tokuda H, Akamatsu S, Iwama T, Kozawa O, Ogura S. Antithrombin 3 suppresses ADP-induced platelet granule secretion: inhibition of HSP27 phosphorylation. Arch. Biochem. Biophys. 2009；489:62-67.
  11. Orimo H, Yaegashi Y, Onoda T, Fukushima Y, Hosoi T, Sakata K. Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos. 2009;4（1-2）:71-77.
  12. Liu M, Kurosaki T, Suzuki M, Enomoto Y, Nishimatsu H, Arai T, Sawabe M, Hosoi T, Homma Y, Kitamura T. Significance of common variants on human chromosome 8q24 in relation to the risk of prostate cancer in native Japanese men. BMC Genet. 2009 ；14;10:37
  13. Kurosaki T, Suzuki M, Enomoto Y, Arai T, Sawabe M, Hosoi T, Homma Y, Kitamura T.Polymorphism of cytochromeP450 2B6 and prostate cancer risk: a significant association in a Japanese population. Int J Urol. 2009 ;16（4）:364-368.
  14. Sawabe M, Arai T, Araki A, Hosoi T, Kuchiba A, Tanaka N, Naito T, Oda K, Ikeda S, Muramatsu M. Smoking confers a MTHFR 677C>T genotype-dependent risk for systemic atherosclerosis: results from a large number of elderly autopsy cases that died in a community-based general geriatric hospital. J Atheroscler Thromb. 2009 ;16（2）:91-104.
  15. Mori S, Kou I, Sato H, Emi M, Ito H, Hosoi T, Ikegawa S. Nucleotide variations in genes encoding carbonic anhydrase 8 and 10 associated with femoral bone mineral density in Japanese female with osteoporosis. J Bone Miner Metab. 2009;27（2）:213-216.

和文原著

  1. 徳田治彦 ： 薬物治療が脊椎骨折予防に果たす役割　Osteoporosis Jpn. 17:173-176, 2009.

2008年

欧文原著

  1. Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Kako H, Ogura S, Kozawa O. Potentiation by platelet-derived growth factor-BB of FGF-2-stimulated VEGF release in osteoblasts.
    J. Bone Miner. Metab. 2008;26:335-341.
  2. Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Harada A, Hosoi T, Ohta T, Kozawa O. （-）-Epigallocatechin gallate inhibits basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts. Horm. Metab. Res. 2008;40:674-678 .
  3. Takai S, Hanai Y, Matsushima-Nishiwaki R, , Minamitani C, Otsuka T, Tokuda H, Kozawa O. P70 S6 kinase negatively regulates FGF-2-stimulated IL-6 synthesis in osteoblasts: function at a point downstream from protein kinase C. J. Endocrinol. 2008;197:131-137.
  4. Hayashi K, Takai S, Matsushima-Nishiwaki R, Hnai Y, Kato K, Tokuda H, Kozawa O. （-）-Epigallocatechin gallate reduces transforming growth factor β-stimulated HSP27 induction through the suppression of stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Life Sci. 2008;82:1012-1017.
  5. Kato K, Takai S, Matsushima-Nishiwaki R, Adachi S, Minamitani C, Otsuka T, Tokuda H, Akamatsu S, Doi T, Ogura S, Kozawa O . HSP27 phosphorylation is correlated with ADP-induced platelet granule secretion. Arch. Biochem. Biophys. 2008;475:80-86.
  6. Minamitani C, Otsuka T, Takai S, Matsushima-Nishiwaki R, Adachi S, Hanai Y, Mizutani J, Tokuda H, Kozawa O. Involvement of rho-kinase in prostaglandin F2α -stimulated interleukin-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. Mol. Cell. Endocrinol.2008;291:27-32.
  7. Minamitani C, Takai S, Matsushima-Nishiwaki R, Hanai Y, Otsuka T, Kozawa O, Tokuda H. Raloxifene-induced acceleration of platelet aggregation. Intern. Med. 2008;47:512-518 .
  8. Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Adachi S, Minamitani C, Mizutani J, Otsuka T, Kozawa O. Function of Rho-kinase in prostaglandin D2 -induced interleukin-6 synthesis in osteoblasts. Prostaglandins Leukot. Essent. Fatty Acids. 2008;79:41-46.
  9. Takai S, Matsushima-Nishiwaki R, Adachi S, Natsume H, Minamitani C, Mizutani J, Otsuka T, Tokuda H, Kozawa O. （-）-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated interleukin-6 synthesis in osteoblasts:suppression of SAPK/JNK.Mediators Inflamm. 2008;2008:291808 .
  10. Urano T, Narusasa K, Shiraki M, Usui T, Sasaki N, Hosoi T, Ouchi Y, Nakamura T, Inoue S . Association of a single nucleotide polymorhisms in the insulin-like growht factor-1 receptor gene with spinal osteoarthritis in postmenopausal Japanese women. Spine. 2008;15;33:1256-1261.
  11. Sogabe N, Oda K, Nakamura H, Orimo H, Watanabe H, Hosoi T, Goseki-Sone M . Molecular effects of the tissue-nonspecific alkaline phosphatase gene polymorphism （787T>C） associated with bone mineral density. Biomed. Res. 2008;29:218-219 .
  12. Arai T, Sawabe M, Hosoi T, Tanaka N . Rold of DNA repair systems in malignant tumor development in the elderly. Geriatr. Gerontol. Int. 2008;8:65-72.
  13. Orimo H, Goseki-Sone M, Hosoi T, Shimada T. Functional assay of the mutant tissue-nonspecific alkaline phosphatase gene using U（2）OS osteoblast-like cells. Mol. Genet. Metab. 2008;94:375-381.
  14. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis A . Development and application of a Japanese model of the WHO fracture risk assessment tool （FRAX）. Osteoporos Int.2008;19:429-435.
  15. Mori S, Kou I, Sato H, Emi M, Ito H, Hosoi T, Ikegawa S . Association of genetic variations of genes encoding thrombospondin, type 1, domain-containing 4 and 7A with low bone mineral density in Japanese women with osteoporosis. J Hum. Genet. 2008;53:694-697.

和文原著

  1. 細井孝之、原田敦、福永仁夫、中村利孝、白木正孝、太田博明、大橋靖雄、藤原佐枝子、坂田清美、堀内敏行、森聖二郎、折茂肇：骨粗鬆症診療の標準的調査項目および全国的データベース構築の検討　Osteoporosis Japan　2008;16:323-329.

2007年

欧文原著

  1. Tokuda H, Takai S, Matsushima-Nishiwaki R, Akamatsu S, Hanai Y, Hosoi T, Harada A, Ohta T, Kozawa O: （-）-Epigallocatechin gallate enhances prostaglandin F2α-induced VEGF synthesis via up- regulating SAPK/JNK activation in osteoblasts. J. Cell. Biochem. 2007; 100:1146-1153. Takai S, Tokuda H, Hanai Y, Kozawa O: Limitation by p70 S6 kinase of PDGF-BB-induced IL-6 synthesis in osteoblast-like MC3T3-E1 cells. Metabolism 2007; 56:476-483.
  2. Takai S, Tokuda H, Hanai Y, Kozawa O: Activation of phosphatidylinositol 3-kinase/Akt limits FGF-2-induced VEGF release in osteoblasts. Mol Cell Endocrinol. 2007; 267:46-54.
  3. Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Hosoi T, Harada A, Ohta T, Kozawa O: （-）-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts: inhibition of p44/p42 MAP kinase activation. FEBS Lett. 2007; 581:1311-1316.
  4. Takai S, Matsushima-Nishiwaki R, Tokuda H, Yasuda E, Toyoda H, Kaneoka Y, Yamaguchi A, Kumada T, Kozawa O: Protein kinase Cδ regulates the phosphorylation of heat shock protein 27 in human hepatocellular carcinoma. Life Sci. 2007; 81:585-591.
  5. Tokuda H, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Doi T, Harada A, Takai S, Kozawa O: Rho-kinase regulates endothelin-1-stimulated IL-6 synthesis via p38 MAPK in osteoblasts. Biochem Biophys Res Commun. 2007; 362:799-804.
  6. Yamauchi J, Takai S, Matsushima-Nishiwaki R, Hanai Y, Doi T, Kato H, Ogura S, Kato K, Tokuda H, Kozawa O: （-）-Epigallocatechin gallate inhibits prostaglandin D2-stimulated HSP27 induction via suppression of the p44/p42 MAP kinase pathway in osteoblasts. Prostaglandins Leukot Essent Fatty Acids. 2007 77:173-179.
  7. Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Akamatsu S, Ohta T, Kozawa O: Platelet-derived growth factor-BB amplifies PGF2α-stimulated VEGF synthesis in osteoblasts: function of phosphatidylinositol 3-kinase. Prostaglandins Leukot Essent Fatty Acids. 2007; 77:187-193.
  8. Takai S, Tokuda H, Hanai Y, Harada A, Yasuda E, Matsushima-Nishiwaki R, Kato H, Ogura S, Ohta T, Kozawa O: Negative regulation by p70 S6 kinase of FGF-2-stimulated VEGF release through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. J Bone Miner Res. 2007; 22:337-346.
  9. Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, Hosoi T, Yoshimura N, Harada N, Younes M, Sakamoto G: Expression of oestrogen receptor-β in apocrine carcinomas of the breast. Histopathology. 2007; 50:425-433.
  10. Ezura Y, Nakajima T, Urano T, Sudo Y, Kajita M, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Emi M: Association of a single-nucleotide variation （A1330V） in the low-density lipoprotein receptor-related protein 5 gene （LRP5） with bone mineral density in adult Japanese women. Bone. 2007; 40:997-1005.
  11. Oda K, Tanakka, Arai T, Araki J, Song Y, Zhang L, Kuchiba A, Hosoi T, Shirasawa T, Muramatsu M, Sawabe M: Polymophisms in pro- and anti-inflammatory cytokine genes and susceptibility to atherosclerosis: pathological sutdy of 1,503 consecutive autopsy cases. Hum Mol Genet. 2007; 16:592-599.
  12. Urano T, Shiraki M, Nakamura K, Usui T, Sasaki N, Hosoi T, Ouchi Y, Nakamura T, Inoue S: Q89R polymorphism in the LDL receptor-related protein 5 gene is associated with spinal osteoarthritis in postmenopausal Japanese women. Spine. 2007; 32:25-29 .
  13. Kinoshita H, Nakgawa K, Narusawa K, Goseki-Sone M, Fukushi-Irie, Mizoi L, Yoshida H, Okano T, Nakamura T, Suzuki T, Inoue S, Orimo H, Ouchi Y, Hosoi T: A functional single nucleotide polymorphism in the vitamin-K-dependent gamma-glutamyl carboxylase gene （Arg325Gln） is associated with bone mineral density in elderly Japanese women. Bone. 2007; 40:451-456.
  14. Kinoshita H, Hirano H, Hosoya A, Ninomiya T, Ozawa H, Sawabe M, Ouchi Y, Yamaguchi M, Hosoi T: Case of bone Paget's disease with cheek pain, hearing loss and tremor whose histological findings showed peculiar calcified structures. Geriatrics and Gerontology International. 2007; 7:189-194 .
  15. Masae Goseki-Sone, Maruyama R, Sogabe N, Hosoi T: Effects of dietary lactose on long-term high-fat-diet-induced obesity in rats. Obesity. 2007; 15:2605-2613.
  16. Urano T, Narusawa K, Shiraki M, Usui T, Sasaki N, Hosoi T, Ouchi Y, Nakamura T, Inoue S: Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women. J Bone Miner Metab. 2007; 25:253-258.
  17. Tamura Y, Araki A, Chiba Y, Mori S, Hosoi T, Horiuchi T: Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab. 2007; 25:226-231.
  18. Sogabe N,Maruyama R, Hosoi T, Goseki-Sone M: Enhancemet effects of vitamin K1 （Phylloquinone） or Vitamin K2 （Menaquuinone-4） on intestinal alkaline phosphatase activity in rats. J Nutritional Science and Vitaminology. 2007; 53:219-224 .
  19. Sogabe N, Tsugawa N, Maruyama R, Kamao M, Kinoshita H, Okano T, Hosoi T, Goseki-Sone M: Nutritional effects of gamma-glutamyl carboxylase gene polymorphism on the correlation between the vitamin K status and gamma-carboxylation of osteocalcin in young males. J Nutritional Science and Vitaminology. 2007; 53:419-425 .

2006年

欧文原著

  1. Takai S, Tokuda H, Matsushima-Nishiwaki R, Hanai Y, Kato K, Kozawa O: Phosphatidylinositol 3-kinase/Akt plays a role in sphingosine 1-phosphate-stimulated HSP27 induction in osteoblasts. J Cell Biochem 2006; 98:1249-1256.
  2. Hanai Y, Tokuda H, Yasuda E, Noda T, Ohta T, Takai S, Kozawa O: Up- regulation by zinc of FGF-2-induced VEGF release throughenhancing p44/p42 MAP kinase activation in osteoblasts. Life Sci. 2006; 80: 230-234.
  3. Takai S, Tokuda H, Hanai Y, Kozawa O: Phosphatidylinositol 3-Kinase /Akt Plays a Part in Tumor Necrosis Factor-α-induced Interleukin -6 Synthesis in Osteoblasts. Horm Metab Res 2006; 38:563-569.
  4. Takai S, Tokuda H, Yoshida M, Yasuda E, Matsushima-Nishiwaki R, Harada A, Kato K, Kozawa O: Prostaglandin D2 induces the phosphorylation of HSP27 in osteoblasts: function of the MAP kinase superfamily. Prostaglandins Leukot Essent Fatty Acids 2006; 75:61-67.
  5. Hanai Y, Tokuda H, Ohta T, Matsushima-Nishiwaki R, Takai S, Kozawa O: Phosphatidylinositol 3-kinase/Akt auto-regulates PDGF-BB- stimulated interleukin-6 synthesis in osteoblasts. J Cell Biochem. 2006; 99:1564-1571.
  6. Hanai Y, Tokuda H, Takai S, Harada A, Ohta T, Kozawa O: Minodronate suppresses prostaglandin F2α -induced vascular endothelial growth factor synthesis in osteoblasts. Horm Metab Res 2006; 38:152-158.
  7. Hanai Y, Tokuda H, Ishisaki A, Matsushima-Nishiwaki R, Nakamura N, Yoshida M, Takai S, Ohta T, Kozawa O: Involvement of p44/p42 MAP kinase in insulin-like growth factor-I-induced alkaline phosphatase activity in osteoblast-like-MC3T3-E1 cells. Mol Cell Endocrinol 2006; 251:42-48.
  8. Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, Katagiri Y, Dohi S, Kozawa O: Modulation by the steroid/thyroid hormone superfamily of TGF-β-stimulated VEGF release from vascular smooth muscle cells. J Cell Biochem 2006; 99:187-195.
  9. Shiraki M, Kuroda T, Nakamura T, Fukunaga M, Hosoi T, Orimo H, Makino K: The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria:the Adequate Treatment of Osteoporosis （A-TOP） Research Group. J Bone Miner Metab. 2006; 24:219-225.
  10. Aklimunnessa K, Mori M, Khan M, Sakauchi F, Kubo T, Fujino Y, Suzuki S, Tokudome S, Tamakoshi A、 for the JACC Study Group: Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women. Jpn J Clin Oncol. 2006; 36: 511-518.
  11. Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, Tanaka F, Tamakoshi A, Sobue G.: Natural history of spinal and bulbar muscular atrophy （SBMA）: a study of 223 Japanese patients. Brain. 2006; 129: 1446-1455.
  12. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Kondo T, Watanabe Y, Koizumi A, Inaba Y, Tamakoshi A; JACC Study Group.: 　Relationships of age at menarche and menopause, and reproductive year with mortality from cardiovascular disease in Japanese postmenopausal women: the JACC study. J Epidemiol. 2006; 16:177-184.
  13. Fujino Y, Iso H, Tamakoshi A, Inaba Y, Koizumi A, Kubo T, Yoshimura T; Japanese Collaborative Cohort Study Group.: A prospective cohort study of shift work and risk of ischemic heart disease in Japanese male workers. Am J Epidemiol.2006; 164:128-135.
  14. Suzuki H, Iwai N, Sakata R, Ichikawa S, Tamakoshi A, for the JACC Study Group: The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer 2006; 94:737-739.
  15. Goto Y, Ando T, Yamamoto K, Tamakoshi A, El-Omar E, Goto H, Hamajima N.: Association between serum pepsinogens and polymorphismof PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese. Int J Cancer. 2006; 118:203-208.
  16. Ikeda A, Iso H, Toyoshima H, Kondo T, Mizoue T, Koizumi A, Inaba Y, Tamakoshi A; JACC Study Group.: Parental longevity and mortality amongst Japanese men and women: the JACC Study. J Intern Med. 2006; 259:285-295.
  17. Related Articles, LinksIso H, Date C, Wakai K, Fukui M, Tamakoshi A; JACC Study Group.: The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med. 2006; 144:554-562.
  18. Ito Y, Suzuki K, Ishii J, Hishida H, Tamakoshi A, Hamajima N, Aoki K: A population-based follow-up study on mortality from cancer or cardiovascular disease and serum carotenoids, retinol and tocopherols in Japanese inhabitants. Asian Pac J Cancer Prev. 2006; 7:533-546
  19. Khan M, Mori M, Fujino Y, Shibata A, Sakauchi F, Washio M, Tamakoshi A; for the Japan Collaborative Cohort （JACC） Study Group.: Site- specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort （JACC） Study. Asian Pac J Cancer Prev.　2006; 7:253-259.
  20. Khan M, Mori M, Sakauchi F, Aklimunnessa K, Kubo T, Fujino Y, Suzuki S, Tokudome S, Tamakoshi A, for the JACC Study Group.: Risk of endometrial cancer mortality by ever-use of sex hormones and other factors in Japan. Asian Pac J Cancer Prev. 2006; 7:260-266.
  21. Khan M, Mori M, Sakauchi F, Matsuo K, Ozasa K, Tamakoshi A; for the JACC Study group:.Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort （JACC） study. Asian Pac J Cancer Prev. 2006; 7:575-581.
  22. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, Miki T, Nakao M, Hayashi K, Suzuki K, Mori M, Washio M, Sakauchi F, Ito Y, Yoshimura T, Tamakoshi A:.Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006; 164:549-555.
  23. Lin Y, Kikuchi S, Tamakoshi A, Kawamura T, Inaba Y, Kurosawa M, Motohashi Y, Yagyu K, Obata Y, Ishibashi T; for the JACC Study Group: Association of menstrual and reproductive factors with pancreatic cancer risk in women: findings of the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. J Gastroenterol. 2006; 41:878-883.
  24. Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y, Kurosawa M, Kawamura T, Motohashi Y, Ishibashi T; for the JACC Study Group.: Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study （Japan）. Cancer Causes Control. 2006; 17:1077-1082.
  25. Lin Y, Kikuchi S, Tamakoshi A, Yagyu K, Obata Y, Inaba Y, Kurosawa M, Kawamura T, Motohashi Y, Ishibashi T: Dietary habits and pancreatic cancer risk in a cohort of middle-aged and elderly Japanese. Nutr Cancer. 2006; 56:40-49.
  26. Marugame T, Kamo K, Sobue T, Akiba S, Mizuno S, Satoh H, Suzuki T, Tajima K, Tamakoshi A, Tsugane S: Trends in smoking by birth cohorts born between 1900 and 1977 in Japan. Prev Med. 2006;42:120-127.
  27. Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuchi K, Kamisawa T, Saisho H, Hirano K, Okamura K, Yanagawa N, Otsuki M.: Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan.　Pancreas. 2006; 32:244-248.
  28. Nishino Y, Wakai K, Kondo T, Seki N, Ito Y, Suzuki K, Ozasa K, Watanabe Y, Ando M, Tsubono Y, Tsuji I, Tamakoshi A; for the JACC Study Group.: Alcohol consumption and lung cancer mortality in Japanese men: results from Japan collaborative cohort （JACC） study.　J Epidemiol. 2006; 16:49-56.
  29. Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, Seki N, Ando M, Nishino Y, Kondo T, Watanabe Y, Ozasa K, Inoue T, Tamakoshi A:. Serum heat shock protein 70 levels and lung cancer risk: a case- control study nested in a large cohort study. Cancer Epidemiol Biomarkers Prev. 2006; 15:1733-1737.
  30. Umesawa M, Iso H, Date C, Yamamoto A, Toyoshima H, Watanabe Y, Kikuchi S, Koizumi A, Kondo T, Inaba Y, Tanabe N, Tamakoshi A:.　Dietary intake of calcium in relation to mortality from cardiovascular disease: the JACC Study. Stroke. 2006; 37:20-26.
  31. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, Ohno Y, Inaba Y, Sakai H: A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study.　Nephrol Dial Transplant. 2006; 21:2800-2808.

和文原著

  1. 徳田治彦、小澤修: 閉経後骨粗鬆症患者における血小板凝集能の検討-薬物療法との関連‐ Osteoporosis　Japan　2006; Vol.14:148-150.
  2. 細井孝之: 3.高齢者における介入試験　3）骨粗鬆症薬物療法の展開　Geriatric Medicine（老年医学） 2006; 44:1697-1702.
  3. 細井孝之: 長寿医療における先端医療のありかた　医療　2006; 60：780-782
  4. 細井孝之: 骨粗鬆症：総論　アルカロイド研究会　会誌 2006; 32:47-52.
  5. 丸田真也、小林拓、平松憲樹、山本明子、永井賢司、玉腰暁子: ステロイド吸入療法における食道カンジタ症に関する臨床的検討. 診断と治療 2006; 94:1241-1245.

欧文総説

  1. Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M: Reviewing the definition of"elderly" Geriatr Gerontol Int 2006; 6:149-158.
  2. Kobashi G, Hoshuyama T, Ohta K, Sugimori H, Oki I, Kanda H, Naito M, Takao S, Tamakoshi A.: Young epidemiologists' attitude towards personal data protection. J Epidemiol. 2006; 16（2）:90-92.

和文総説

  1. 細井孝之: 骨粗鬆症. Medicina 43（増刊号） 2006; 577-579.
  2. 細井孝之: Wnt共受容体LRP5と骨粗鬆症. 内分泌・糖尿病科 2006; 22:219-222.
  3. 細井孝之、藤原佐枝子、井樋英二: 骨粗鬆症診療の展望. カレントテラピー 2006; 24:73-78.
  4. 細井孝之: 骨粗鬆症の診断. クリニカルプラクティス 2006; 25:661-664.
  5. 折茂肇、細井孝之、水沼英樹、武藤芳照: 骨粗鬆症の予防. THE BONE 2006; 20：121-133.
  6. 伊藤宜則、玉腰暁子: 疫学からみたプロビタミンAとがん. Biotherapy 2006; 20:134-142.
  7. 玉腰暁子: 疫学･臨床研究に対する理解とヘルスリテラシー. からだの科学 2006; 250;63-67.
  8. 玉腰暁子: 脳卒中･心臓病の予防．健康長寿と運動. Advances in Aging and Health Research 2005. 財団法人長寿科学振興財団 2006; 111-117

著書

  1. 玉腰暁子: 疫学研究に関する倫理指針. 日本病院管理学会学術情報委員会（編）．医療･病院管理用語辞典[改訂第3版] 東京:エルゼビア･ジャパン 2006; pp48.

2005年

欧文原著

  1. Kanno Y, Ishisaki A, Yoshida M, Tokuda H, Kozawa O: SAPK/JNK plays a role in transforming growth factor-β-induced VEGF synthesis in osteoblasts. Horm Metab Res 2005; 37:140-145, 2005.
  2. Kanno Y, Ishisaki A, Yoshida M, Nakajima K, Tokuda H, O Numata, Kozawa O: Adenylyl cyclase-cAMP system inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts.　 Mol Cell Endocrinol 2005; 229:75-82.
  3. Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O: P2Y12 receptors play a significant role on the development of platelet micro-aggregation in patients with diabetes. J Clin Endocrinol Metab 2005; 90: 920-927.
  4. Yoshida M, Kanno Y, Ishisaki A, Tokuda H, Hirade K, Nakajima K, Katagiri Y, Shimizu K, Kozawa O: Methotrexate suppresses inflammatory agonists-induced interleukin-6 synthesis in osteoblasts. J Rheumatology 2005; 32:787-795.
  5. Yasuda E, Tokuda H, Ishisaki A, Hirade K, Kanno Y, Hanai Y, Nakamura N, Noda T, Katagiri Y, Kozawa O: PPAR-gamma ligands up-regulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/JNK activation in osteoblasts. Biochem Biophys Res Commun 2005; 328:137-143.
  6. Noda T, Tokuda H, Yoshida M, Yasuda E, Hanai Y, Takai S, Kozawa O: Possible involvement of phosphatidylinositol 3-kinase/Akt pathway in insulin-like growth factor-I-induced alkaline phosphatase activity in osteoblasts. Horm Metab Res; 2005 37:270-274.
  7. Yoshida M, Tokuda H, Ishisaki A, Kanno Y, Harada A, Shimuzu K, Kozawa O: Tiludronate inhibits prostaglandin F2α -induced vascular endothelial growth factor synthesis in osteoblasts. Mol Cell Endocrinol 2005 ;236:59-66.
  8. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki M, Ichimura S, Nakatsuka K, Miura M, for the Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis, Japan Osteoporosis Society: Guidelines on the use of biochemical markers of bone turnover in osteoporosis（2004）. J Bone Miner Metab 2005; 23:97-104.
  9. Urano T, Shiraki M, Fujita M, Sekine E, Hosoi T, Orimo H, Ouchi Y, Inoue S : Association of a single nucleotide polymorphism in the lipoxigenase ALLOX115 5'-flanking region （-5229G/A） with bone mineral density 2005 J Bone Miner Metab 2005; 23: 226-230.
  10. Goseki-Sone M, Sogabe N, Fukushi-Irie M, Mizoi L, Hideo Orimo, Suzuki T, Nakamura H, Orimo H, Hosoi T: Functional analysis of the single-nucleotide polymorphism （787T>C） in tissue-nonspecific alkaline phosphatase gene associated with bone mineral density. J Bone Miner Res 2005; 20: 773-782.
  11. Araki A, Hosoi T, Orimo H, Ito H: Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism 2005; 54:809-14.
  12. Yoshimura N, Suzuki T, Hosoi T, Orimo H: Epidemiology of hip fracture in Japan: incidence and risk factors. J Bone Miner Metab. 2005; 23 Suppl:78-80.
  13. Suzuki M, Mamun MR, Hara K, Ozeki T, Yamada Y, Kadowaki T, Honda H, Yanagihara Y, Ito YM, Kameyama S, Ohta N, Hosoi T, Arai T, Sawabe M, Takeuchi T, Takahashi S, Kitamura T: The Val158Met Polymorphism of the Catechol-O-methyltransferase Gene is Associated with the PSA-Progression-Free Survival in Prostate Cancer Patients Treated with Estramustine Phosphate. Eur Urol 2005 Aug 25; [Epub ahead of print]
  14. Ito M, Ikeda K, Nishiguchi　M, Shindo H, Uetani M, Hosoi T, Orimo H: Multi-Detector Row CT Imaging of Vertebral Microstructure for Evaluation of Fracture Risk. J Bone Miner Res. 2005; 20:1828-36.

和文原著

  1. 内敏行、小林義雄、細井孝之、石橋英明、山本精三、矢富直美: 骨粗鬆症患者におけるQOL尺度の信頼性、妥当性の検討ーEOQOLによる高齢骨粗鬆症QOL評価ー. 日本老年医学会雑誌2005; 42:229-234.
  2. 三谷和子、吉野正俊、山之内博、浜崎健、林泰史、細井孝之、高橋英気、村上喜生、村山繁雄、本間尚子、沢辺元司: 首下がりにて発症し、急性呼吸不全を呈し臨床的に筋萎縮性側索硬化症を疑った高齢女性例. 内科2005; 95: 931-941.

和文総説

  1. 細井孝之：骨粗鬆症の遺伝的素因とは、ホルモンと臨床2005; 53: 425-431.
  2. 田村嘉章、細井孝之：骨におけるインスリン作用. 内分泌・糖尿病科2005; 20: 167-171.
  3. 細井孝之：Wnt共受容体LRP5遺伝子と骨粗鬆症. 日本内科学会雑誌 2005; 94: 108－113.
  4. 細井孝之：骨粗鬆症治療薬　ビタミンD3製剤のもつエビデンスとその使い方. Modern Physician 2005; 25: 735ー738.
  5. 細井孝之：骨粗鬆症の診断基準. 臨床と研究2005; 82: 915-920.
  6. 細井孝之：高齢者ケアのガイドライン　腰痛. ジェロントロジーニューホライズン 2005;　17: 251-254.
  7. 細井孝之：特集　日常診療で困ることあれこれ　高齢者診療編. 研修医通信 2005; no.5: 4-7.
  8. 細井孝之：質疑応答　骨粗鬆症治療薬の併用. 日本医事新報 2005;　no. 4231. p86.
  9. 細井孝之：連載5　骨粗鬆症と生活習慣　骨粗鬆症と魚、魚肉摂取. CLINICAL　CALCIUM 2005; 5:500-502.
  10. 細井孝之：特集　骨粗鬆症と遺伝子　巻頭言. CLINICAL　CALCIUM 2005; 5:,735.
  11. 細井孝之：遺伝子多型性を用いた骨量決定遺伝子の探索ー現状と課題. CLINICAL　CALCIUM 2005; 5: 753-761.
  12. 細井孝之：コーヒー摂取と骨折. からだの科学 2005; 244: 56-60.
  13. 細井孝之：骨粗鬆症治療における遺伝子多型の応用. 臨床医薬 2005; 21: 826（62）.
  14. 細井孝之：高齢者の骨折予防とビタミンD　解説. The Mainichi Medical Journal 2005; 1: 553.
  15. 細井孝之：骨粗鬆症にかかわる遺伝多型. ホルモンと臨床 2005; 53: 21-27.
  16. 細井孝之：Ca拮抗薬と骨代謝. CLINICAL　CALCIUM 2005; 15: 103-107.
  17. 細井孝之：病態と疾患からみたカルシトニン　骨粗鬆症. 日本臨床（増刊号）　臨床分子内分泌学?B－甲状腺・副甲状腺・骨内分泌代謝系ー　2005; 63, suppl 10: 215-218.
  18. 細井孝之：第25回日本臨床薬理学会年会記録　シンポジウム9：遺伝子多型解析の成果による臨床応用の新展開　5．骨粗鬆症診療における遺伝子多型の応用. 臨床薬理 2005; 36: 71S-72S

著書

  1. 細井孝之：腰痛. 日常診療に活かす老年病ガイドブック1　老年症候群の診かた（大内尉義監修）　メジカルビュー社, 東京, 2005, p195－198.
  2. 細井孝之：第13章骨・運動器疾患. 標準理学療法学・作業療法学　専門基礎分野　老年学　第2版 （大内尉義編集）　医学書院, 東京, 2005, p146-157.
  3. 細井孝之：骨粗鬆症検診の落とし穴ー前腕骨と腰椎BMDの差など. 更年期医療のコツと落とし穴 （麻生武志 編集）. 中山書店, 東京, 2005, p55.
  4. 細井孝之：骨粗鬆症の検診とドック . 骨粗鬆症の診断と鑑別ー骨密度測定と脊椎画像診断ー （福永仁夫 編集）　医薬ジャーナル社, 大阪, 2005, p133-137.
  5. 細井孝之：翻訳：骨粗鬆症. ケンブリッジ　世界の食物史大百科事典　第3巻 （小林彰夫　監訳）　朝倉書店, 東京, 2005, p451－466.
  6. 細井孝之：第11章筋骨格疾患. スタンダード栄養・食物シリーズ13臨床栄養学各論 （小松龍史、近藤和雄、脊山洋右、森田寛 編集）, 東京化学同人, 東京, 2005, p153－157.
  7. 細井孝之：骨粗鬆症の遺伝的背景. 日常診療に活かす老年病ガイドブック?D骨粗鬆症と骨折予防. （大内尉義 監修, 大内尉義、井藤英喜、三木哲郎、鳥羽研二 編集）, Medical View社, 東京, 2005, p42－45.
  8. 細井孝之：イプリフラボン. 日常診療に活かす老年病ガイドブック?D骨粗鬆症と骨折予防（大内尉義 監修,　大内尉義、井藤英喜、三木哲郎、鳥羽研二 編集）, Medical View社, 東京, 2005, p115－118.

2004年以前

欧文原著

  1. Tokuda H, Niwa M, Ishisaki A, Nakajima K, Ito H, Kato K, Kozawa O: Involvement of Stress-activated protein kinase （SAPK）/c-Jun N terminal kinase （JNK） in prostaglandin F2α-induced heat shock protein 27 in osteoblasts. Prost Leukot Essent Fatty Acids 2004; 70:441-447.
  2. Ishisaki A, Tokuda H, Yoshida M, Kunieda K, Hatakeyama D, Shibata T, Kozawa O: Activation of p38 mitogen-activated protein kinase mediates thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. Mol Cell Endocrinol 2004; 214:189-195.
  3. Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O: Interleukin （IL）-17 enhances tumor necrosis factor-alfa-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem 2004; 91:1053-1061.
  4. Kanno Y, Tokuda H, Nakajima K, Ishisaki A, O Numata, Kozawa O: Involvement of SAPK/JNK in prostaglandin E1-induced VEGF synthesis in osteoblast-like cells. Mol Cell Endocrinol 2004; 220:89-95.
  5. Harada A, Matsui Y, Mizuno M, Tokuda H, Niino N, Ohta T: Japanese Orthopedistsﾕ interests in prevention of fractures in the elderly from falls. Osteoporosis Int 2004; 15:560-566.
  6. Tokuda H, Kato K, Oiso Y, Kozawa O: Contrasting effects of triiodothyronine on heat shock protein 27 induction and vascular endothelial growth factor synthesis stimulated by TGF-β in osteoblasts. Mol Cell Endocrinol 2003; 201:33-38.
  7. Tokuda H, Hirade K, Wang X, Oiso Y, Kozawa O: Involvement of SAPK/JNK in basic fibroblast growth factor-induced VEGF release in osteoblasts. J Endocrinol 2003; 177:101-107.
  8. Tokuda H, Hatakeyama D, Shibata T, Akamtasu S, Oiso Y, Kozawa O: p38 MAP kinase regulates BMP-4-stimulated VEGF synthesis via p70 S6 kinase in osteoblasts. Am J Physiol （Endocrinol Metab） 2003; 286: E1202-1209.
  9. Tokuda H, Harada A, Hirade K, Matsuno H, Ito H, Kato K, Oiso Y, Kozawa O: Incadronate amplifies prostaglandin F2α-induced vascular endothelial growth factor synthesis in osteoblasts: enhancement of MAP kinase activity. J Biol Chem 2003; 278:18930-18937.
  10. Wang X, Tokuda H, Hatakeyama D, Hirade K, Niwa M, Ito H, Kato K, Kozawa O: Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch Biochem Biophys 2003; 415:6-13.
  11. Tokuda H, Hatakeyama D, Akamtasu S, Tanabe K, Yoshida M, Shibata T, Kozawa O: Involvement of MAP kinases in TGF-β-stimulated vascular endothelial growth factor synthesis in osteoblasts. Arch Biochem Biophys 2003; 415:117-125.
  12. Tokuda H, Niwa M, Ito H, Kato K, Kozawa O: Involvement of stress-activated protein kinase/c-Jun-terminal kinase in endothelin-1-induced heat shock protein 27 in osteoblasts. Eur J Endocrinol 2003; 149:239-245.
  13. Tokuda H, Kozawa O, Niwa M, Matsuno H, Kato K, Uematsu T: Mechanism of prostaglandin E2-stimulated heat shock protein 27 induction in osteoblast-like MC3T3-E1 cells. J Endocrinol 2002; 172:271-281.
  14. Tokuda H, Kozawa O, Uematsu T : Interleukin （IL）-17 enhances prostaglandin F2-α-stimulated IL-6 synthesis in osteoblasts. Prost Leukot Essent Fatty Acids 2002; 66:427-433.
  15. Kozawa O, Niwa M, Hatakeyama D, Tokuda H, Matsuno H, Kato K, Uematsu T: Specific induction of heat shock protein 27 by glucocorticoid in osteoblasts. J Cell Biochem 2002; 86:357-364.
  16. Wang X, Tokuda H, Hirade K, Kozawa O: Stress-activated protein kinase/c-Jun N-terminal kinase （JNK） plays a part in endothelin-1-induced vascular endothelial growth factor synthesis in osteoblasts. J Cell Biochem 2002; 87:417-423.
  17. Kozawa O, Hatakeyama D, Tokuda H, Oiso Y, Matsuno H, Uematsu T: Sphingomyelinase amplifies BMP-4-induced osteocalcin synthesis in osteoblasts: role of ceramide. Cell Signal 2002; 14:999-1004.
  18. Harada A, Mizuno M, Takemura M, Tokuda H, Okuizumi H, Niino N: Hip fracture prevention trial using hip protector in Japanese nursing homes. Osteoporosis Int 2001; 12:215-221.
  19. Tokuda H, Kozawa O, Miwa M, Uematsu T: p38 Mitogen-activated protein （MAP） kinase but not p44/p42 MAP kinase is involved in prostaglandin E1-induced vascular endothelial growth factor （VEGF） synthesis in osteoblasts. J Endocrinol 2001; 170:629-638.
  20. Miwa M, Tokuda H, Uematsu T: Involvement of arachidonic acid in chemical stress-induced interleukin-6 synthesis in osteoblast-like cells: comparison with heat shock protein 27 induction. Prost Leukot Essent Fatty Acids 2000; 62:189-93.
  21. Tokuda H, Kozawa O, Uematsu T: Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: divergent regulation by p42/p44 MAP kinase and p38 MAP kinase. J Bone Miner Res 2000; 15:2371-2379.
  22. Tokuda H, Kozawa O, Harada A, Uematsu T: Extracellular sphingomyelinase induces interleukin-6 synthesis in osteoblasts. J Cell Biochem 1999; 72:262-268.
  23. Tokuda H, Kozawa O, Harada A, Uematsu T: p42/p44 Mitogen-activated protein kinase activation is involved in prostaglandin F2-alfa-induced interleukin-6 synthesis in osteoblasts. Cell Signal 1999; 11:325-330.
  24. Kawamura H, Ohtsuka T, Tokuda H, Matsuno H, Niwa M, Matsui N, Uematsu T, Kozawa O: Involvement of p42/p44 MAP kinase in endothelin-1-induced interleukin-6 synthesis in osteoblast-like cells. Bone 1999; 24:315-320.
  25. Shinoda J, Kozawa O, Tokuda H, Uematsu T: Effect of ceramide on interleukin-6 synthesis in osteoblast-like cells. Cell Signal 1999; 11:435-441.
  26. Kozawa O, Tokuda H, Matsuno H, Uematsu T: Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts. J Cell Biochem 1999; 74:479-485.
  27. Kozawa O, Niwa M, Matsuno H, Tokuda H, Miwa M, Ito H, Kato K, Uematsu T: Sphingosine 1-phosphate induces heat shock protein 27 via p38 mitogen-activated protein kinase activation in osteoblasts. J Bone Miner Res 1999; 14:1761-1767.
  28. Kozawa O, Tokuda H, Miwa M, Ito H, Matsuno H, Niwa M, Uematsu T: Involvement of p42/p44 mitogen-activated protein kinase in prostaglandin F2-alfa-stimulated induction of heat shock protein 27 in osteoblasts. J Cell Biochem 1999; 75:610-619.
  29. Tokuda H, Kozawa O, Harada A, Uematsu T: Prostaglandin D2 induces interleukin-6 synthesis via Ca2+ mobilization in osteoblasts: regulation by protein kinase C. Prost Leukot Essent Fatty Acids 1999; 61:189-194.
  30. Miwa M, Kozawa O, Tokuda H, Uematsu T: MAP kinases are involved in IL-1-induced IL-6 synthesis in osteoblasts: Modulation not of p38 MAP kinase but of p42/p44 MAP kinase by IL-1-activated protein kinase C. Endocrinology 1999; 140:5120-5125.
  31. Matsuno M, Kozawa O, Suzuki A, Tokuda H, Kaida T, Matsuno H, Niwa M, Uematsu T: Involvement of protein kinase C activation in endothelin-1-induced secretion of interleukin-6 in osteoblast-like cells. Cell Signal 1998; 10:107-111.
  32. Tokuda H, Kozawa O, Harada A, Isobe K, Uematsu T: Triiodothyronine modulates interleukin-6 synthesis in osteoblasts: Inhibitions in protein kinase A and C pathways. Endocrinology 1998; 139:1300-1305.
  33. Kozawa O, Tokuda H, Kaida T, Matsuno H, Uematsu T: Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts. Prost Leukot Essent Fatty Acids 1998; 58:119-123.
  34. Tokuda H, Kozawa O, Harada A, Uematsu T: Tiludronate inhibits interleukin-6 synthesis in osteoblasts: Inhibition of phospholipase D activation in MC3T3-E1 cells. J Cell Biochem 1998; 69:252-259.
  35. Kozawa O, Suzuki A, Tokuda H, Kaida T, Uematsu T: Interleukin-6 synthesis induced by prostaglandin E2: Cross-talk regulation by protein kinase C. Bone 1998; 22:355-360.
  36. Kozawa O, Tokuda H, Kaida T, Matsuno H, Uematsu T: Retinoic acid suppresses interleukin-6 synthesis induced by prostaglandins in osteoblasts. Prost Leukot Essent Fatty Acids 1998; 58:215-219.
  37. Kozawa O, Tokuda H, Matsuno H, Uematsu T: Sphingosine modulates interleukin-6 synthesis in osteoblasts. J Cell Biochem 1998; 70:338-345.
  38. Kozawa O, Suzuki A, Tokuda H, Uematsu T: Prostaglandin F2-alfa stimulates interleukin-6 synthesis via activation of PKC in osteoblast-like cells. Am J Physiol 1997; 272 （Endocrinol. Metab. 35）:E208-E211.
  39. Kozawa O, Tokuda H, Kaida T, Matsuno H, Uematsu T: Thrombin regulates interleukin-6 synthesis through phosphatidylcholine hydrolysis by phospholipase D in osteoblasts. Arch Biochem Biophys 1997; 345:10-15.
  40. Kozawa O, Suzuki A, Tokuda H, Kaida T, Uematsu T: Protein kinase C activation by interleukin （IL）-1 limits IL-1-induced IL-6 synthesis in osteoblast-like cells: Involvement of phosphatidylcholine-specific phospholipase C. J Cell Biochem 1997; 67:103-111.
  41. Kozawa O, Suzuki A, Kaida T, Tokuda H, Uematsu T: Tumor necrosis factor-alfa autoregulates interleukin-6 synthesis via activation of protein kinase C: Function of sphingosine 1-phosphate and phosphatidylcholine-specific phospholipase C. J Biol Chem 1997; 272:25121-25126.
  42. Kozawa O, Tokuda H, Matsuno H, Uematsu T: Activation of mitogen-activated protein kinase is involved in sphingosine 1-phosphate-stimulated interleukin-6 synthesis in osteoblasts. FEBS Lett 1997; 418:149-151.
  43. Tokuda H, Suzuki A, Watanabe-Tomita Y, Shinoda J, Imamura Y, Igata A, Kozawa O: Function of Ca2+ in phosphatidylcholine-hydrolyzing phospholipase D activation in osteoblast-like cells. Bone 1996; 19:347-352.
  44. Watanabe Y, Tokuda H, Suzuki A, Shinoda J, Kotoyori J, Ito Y, Oiso Y, Kozawa O: Glucocorticoid amplifies vasopressin-induced phosphoinositide hydrolysis in aortic smooth muscle cells. J Cell Biochem 1995; 57:522-529.
  45. Kozawa O, Suzuki A, Tokuda H: Pituitary adenylate cyclase-activating polypeptide autoregulates cAMP production due to activation of protein kinase C in PC12 pheochromocytoma cells. Horm Metab Res 1995; 27:110-112.

和文原著

  1. 村本あき子, 徳田治彦, 中村麻友美, 鈴木明子, 松井康素, 岡村菊夫: 大腿骨頭壊死を呈した男性Cushing症候群の１例. 内科 2004; 595-597.
  2. 鈴木明子, 中村麻友美, 村本あき子, 徳田治彦: 骨量減少および骨代謝マーカーの高値を認めた男性Kalmann症候群の1例. 新薬と臨床 2003; 52: 1387-1392.
  3. 飯野昌樹, 徳田治彦, 近藤紀子, 加知輝彦, 安井章裕: 脊髄小脳変性症に合併した原発性副甲状腺機能亢進症の１例. 内科　1999; 83:397-400.

欧文総説

  1. Kozawa O, Tokuda H, Kato K, Uematsu T: Heat shock protein 27 in osteoblasts: Mechanism of heat shock protein 27 induction. Recent Res. Devel. Biophys. Biochem. 2002; 2:27-31.

和文総説

  1. 太田壽城、中村範美：わが国全体の骨粗鬆症への取り組み. CLINICAL CALCIUM 2004; 14: 1668-1670.
  2. 徳田治彦：高齢期の骨粗鬆症対策. CLINICAL CALCIUM 2004; 14:1727-1731.
  3. 徳田治彦、原田　敦：骨粗鬆症の病型分類. 日本臨床 2004; 62 （suppl 2）: 249-253.
  4. 管野陽介、徳田治彦、石崎　明、小澤　修：退行期骨粗鬆症とその治療. 東海産婦人科学会雑誌 2004; 40: 9-13.
  5. 小澤　修、徳田治彦：骨代謝とストレスタンパク質（heat shock protein 27: HSP27）. 日本薬理学会会誌2002; 119:89-94.
  6. 小澤 修、徳田治彦：骨芽細胞におけるＰＫＣ. 生体の科学1998; 49:269-273.

 

先頭へ戻る